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A positive correlation exists between increasing age and the incidence of 
hippocampal-associated dysfunction and disease. Normal L-glutamate 
neurotransmission is absolutely critical for hippocampal function, while abnormal 
glutamate neurotransmission has been implicated in many neurodegenerative 
diseases.   Previous studies, overwhelmingly utilizing ex vivo methods, have 
filled the literature with contradicting reports about hippocampal glutamate 
regulation during aging.  For our studies, enzyme-based ceramic microelectrode 
arrays (MEA) were used for rapid (2 Hz) measurements of extracellular 
glutamate in the hippocampal trisynaptic pathway of young (3-6 months), late-
middle aged (18 mo.) and aged (24 mo.) urethane-anesthetized Fischer 344 rats.  
Compared to young animals, glutamate terminals in cornu ammonis 3 (CA3) 
showed diminished potassium-evoked glutamate release in aged rats.  In late-
middle aged animals, terminals in the dentate gyrus (DG) showed increased 
evoked release compared to young rats.  The aged DG demonstrated an 
increased glutamate clearance capacity, indicating a possible age-related 
compensation to deal with the increased glutamate release that occurred in late-
middle age.   
To investigate the impact of changes in glutamate regulation on the 
expression of a disease process, we modified the MEA technology to allow 
recordings in unanesthetized rats.  These studies permitted us to measure 
glutamate regulation in the hippocampal formation without anesthetic effects, 
which showed a significant increase in basal glutamatergic tone during aging.  
Status epilepticus was induced by local application of 4-aminopyridine.  Real-
time glutamate measurements allowed us to capture never-before-seen 
spontaneous and highly rhythmic glutamate release events during status 
epilepticus.  A significant correlation between pre-status tonic glutamate and the 
quantity of status epilepticus-associated convulsions and glutamate release 
events was determined.  Taken together, this body of work identifies the DG and 
CA3 as the loci of age-associated glutamate dysregulation in the hippocampus, 
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 and establishes elevated levels of glutamate as a key factor controlling severity 
of status epilepticus in aged animals. 
Based upon the potential ability to discriminate brain areas experiencing 
seizure (i.e. synchronized spontaneous glutamate release) from areas not, we 
have initiated the development of a MEA for human use during temporal lobe 
resection surgery.  The final studies presented here document the development 
and testing of a human microelectrode array prototype in non-human primates.     
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    Real-time Amperometry 
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Chapter One: Introduction 
 
 The hippocampus, the brain area chiefly responsible for cognitive learning 
and memory, undergoes many biological changes during aging.  Age-associated 
declines in learning and memory have been well established in humans and 
demonstrated in non-human primate and rodent models of human aging.  Much 
is known about the morphological, biochemical and electrophysiological changes 
that occur during aging in the hippocampus, but an understanding about how 
these age-associated changes translate into deficits in the cognitive functions of 
the hippocampus is largely lacking.  The hippocampus is also a primary substrate 
for the onset of age-associated pathology like Alzheimer’s disease.  Changes in 
cognitive function and on-set of disease, have led to the hypothesis that 
hippocampal aging and the associated biological changes may increase the 
susceptibility of aging populations to hippocampal dysfunction and 
neurodegenerative disease.    
 
Anatomy and Neurophysiology of the Trisynaptic Pathway 
 
 The trisynaptic pathway or circuit is an ensemble of extrinsic and intrinsic 
pathways that adjoin cytoarchitectonically distinct regions in the hippocampal 
formation.  All of the neuronal communication in the trisynaptic circuit is 
excitatory, using the neurotransmitter L-glutamate (Storm-Mathison, 1977).  As 
described by Andersen and colleagues (2007), fast excitatory neurotransmission 
is mediated primarily by inward excitatory postsynaptic currents (EPSCs) flowing 
through ionotropic α-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionate (AMPA) 
glutamate receptors, while slower hippocampal EPSCs are the result of 
activation of N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors and 
certain subtypes of metabotropic glutamate receptors (mGluRs).  The NMDA and 
AMPA ionotropic glutamate receptors are critical for long-term potentiation, 
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plasticity and hippocampal-dependent learning and memory (for review see 
Riedel et al., 2003).   
 Synapse 1 of the trisynaptic circuit is at the terminal end of projections 
from the entorhinal cortex (EC) to the dentate gyrus (DG); synapse 2 at the end 
of DG projections to cornu ammonis 3 (CA3) and synapse 3 at the end of CA3 
projections to cornu ammonis 1 (CA1) (Anderson et al., 1971).  Each set of 
projections in the trisynaptic circuit is named.  The major input projections into 
the DG, termed the perforant path, arise from layer II of the EC (with minor layer 
V and VI contributions) (Steward and Scoville, 1976).  Perforant path projections 
terminate in the molecular layer of the DG which contains the dendrites of the 
principal cell type in the DG, granule cells.  The DG houses other cell types, most 
of which are inhibitory neurons, but only the granule cells provide axons that 
project outside of the DG.  Granule cells provide efferents termed mossy fibers 
that only project to dendrites of CA3 principle cells, known as pyramidal cells 
(Claiborne et al., 1986).  CA3 pyramidal cells project to dendrites of CA1 
pyramidal cells via Schaffer collaterals (Ishizuka et al., 1990) (Figure 1.1).   
 Outside of the trisynaptic circuit, it is necessary to note that CA3 receives 
input from the perforant path in a similar manner to the DG which may actually be 
the major determinant of CA3 output (Yeckel and Berger, 1990; Witter, 1993).  
Also, CA3 is heavily innervated by ‘associational connections/ collaterals’ from 
other CA3 pyramidal neurons (Hasselmo et al., 1995).  CA1 also receives 
perforant path afferents from the EC, which are unique because they originate in 
layer III (Andersen et al., 2007).  A ‘loop’ of interconnectivity is created 
throughout the hippocampal formation when CA1 pyramidal cells project to the 
subiculum, which as a major source of hippocampal output projects back to all 
layers of the EC (Andersen et al., 2007).  Other neurotransmitters in the 
hippocampus can modulate the flow of excitatory neurotransmission, namely 
acetylcholine (ACh).  Ionotropic (nicotinic) ACh receptors can modulate 
glutamate release due to their positioning on presynaptic glutamatergic fibers 
and on inhibitory interneurons.  Metabotropic (muscarinic) ACh receptors can be 
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found pre- and post-synaptically, and their effects are extremely excitatory 
(reviewed by Shepherd, 2004).   
  Though the DG, CA3 and CA1 subregions of the trisynaptic circuit are 
intricately connected, they each have unique characteristics distinguishing them 
from the other regions.  This necessitates experimental protocols that investigate 
them individually, as opposed to studying the hippocampal formation as a 
homogeneous structure.  Pyramidal cells in CA3 and CA1 differ from each other 
and from DG granule cells both anatomically and biophysically (Carnevale, et al. 
1997).  The most recent evidence of subregional differences has come from 
Greene and colleagues (2009).  Using laser-capture microdissection and 
microarray hybridization, it was shown that greater than 45% of expressed gene 
transcripts were significantly different across the DG, CA3 and CA1 principal 
layers, and one third of those (>1000) showed at least a two-fold difference 
between layers.  In the CA3 pyramidal layer, transcripts encoding proteins 
involved in glucose metabolism were highly expressed, and in the DG transcripts 
related to MAP kinase signaling and transcriptional regulator activity were most 
prominent.  Differences between CA3 and CA1 included alterations in transcripts 
for calcium and potassium channels and glutamate receptors.  Also, more 
synapse-related transcripts were expressed in CA3 compared to CA1.  Greene et 
al. (2009) emphasized that functional differences across cell layers were likely 
secondary to wide-ranging expression differences of modest magnitude, rather 
than very large disparities in a few genes, but points out that these differences 
may be enough to account for subregion-specific susceptibility to insult including 
DG granule cell resistance to damage following ischemia and seizures, CA3 
pyramidal cell vulnerability to damage from trauma and seizure and CA1 
pyramidal cell vulnerability to ischemia and seizure (Ordy et al., 1993; Borges et 
al., 2007)  
 Overall, the trisynaptic circuit architecture and patterns of connectivity are 
similar between rats and humans.  Humans do have a much expanded CA1 
pyramidal cell layer (30 cells thick in humans, 5 cells thick in rats), and more 
developed entorhinal cortex (8 distinct subregions vs. 2 subregions) compared to 
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rats (Andersen et al., 2007).  Rats have extensive commissural connections 
between the DG in each hemisphere (Gottlieb and Cowan, 1973), and though 
less numerous, humans also have these connections, which can allow 
contralateral seizure propagation (Gloor et al., 1993).  Other minor differences 
exist, but overall the hippocampal formation is a phylogenetically conserved brain 
region in mammals (Andersen et al., 2007). 
 
Anatomic and Neurophysiologic Changes in the Aged Hippocampus 
 
 Though some reports have shown a loss of hippocampal principal neurons 
during aging (for review see Geinisman et al., 1995), widespread use of unbiased 
stereological cell counting methods have contributed several studies to the 
literature that indicate no age-related loss of principal cells occurs in rats (Rapp 
and Gallagher, 1996; Rasmussen et al., 1996;), non-human primates (West et 
al., 1993; Peters et al., 1996), or humans (West, 1993; Morrison and Hof, 1997).  
Also, Rapp et al. (2002) found that aged rats with spatial learning deficits 
maintain neuron numbers at young levels in the primary input to the 
hippocampus, the EC.  In addition to preserved number, several of the basic 
cellular characteristics of granule and pyramidal principal cells do not change 
with age (reviewed by Rosenzweig and Barnes, 2003) including but not limited 
to, resting membrane potential (Barnes, 1979; Barnes et al., 1987, 1992; Potier 
et al., 1992), and amplitude and duration of Na+ -mediated action potentials 
(Barnes and McNaughton, 1980; Segal, 1982; Barnes et al., 1987, 1992; Niesen 
et al., 1988; Potier et al., 1992).  Alterations in hippocampal function do not 
appear to be caused by gross changes in cell numbers or basic cellular 
characteristics, therefore research efforts have shifted to focus on synapses as a 
substrate for hippocampal dysfunction. 
 Important changes in synaptic function are believed to occur in the aged 
trisynaptic circuit related to alterations in synapse number, efficiency and calcium 
regulation.  Changes are subregion specific.  A loss of perforant path axons 
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(Barnes and McNaughton, 1980) and synapses (Geinisman et al., 1992) in the 
DG has been demonstrated.  Compensatory increases in the strength of the 
remaining synapses, shown by changes in the presynaptic fiber/EPSP ratio 
(Barnes and McNaughton, 1980, Foster et al., 1991) and increased quantal size 
(Foster et al., 1991), indicates that remaining perforant path synapses in aged 
rats may be stronger than in young rats.  A loss of Schaffer collateral synapses 
are also believed to occur in CA1 based upon electrophysiological data 
(Landfield et al., 1986; Barnes et al., 1992; Deupree et al., 1993); however, 
different from the synapses in the DG, the CA1 synapse are not believed to 
increase in strength (reviewed by Rosenzweig and Barnes, 2003).  Functional 
outcomes of age-associated synaptic changes are believed to correspond to 
changes in long-term potentiation (LTP), a mechanism underlying learning and 
memory processes in the laboratory setting (Moser et al., 1998).  LTP is a long-
lasting augmentation of synaptic responses following high frequency stimulation 
(Bliss and Gardner-Medwin, 1973).   
 Using high intensity stimulation protocols, synapses in the DG of young 
and aged animals have been shown to reach the same maximum LTP, though 
the process took longer in aged animals and aged animals lost the LTP faster 
(Barnes and McNaughton, 1985; Diana et al., 1994)).  Similar to the DG, the 
maximum potentiation obtained in CA1 of young and aged animals is the same, 
though the time to reach peak potentiation is longer in aged rats (Landfield et al., 
1978).  The age-associated changes in the DG and CA1 LTP have been 
replicated many times.  Interestingly, an opposite process of LTP, long-term 
depression (LTD) reduces synaptic strength, and is the experimental equivalent 
of erasing a memory (reviewed by Rosenzweig and Barnes, 2003).  Aged 
animals have been shown to be more susceptible to LTD (Norris et al., 1996), so 
based upon LTP and LTD studies, aged animals not only have more difficultly 
learning or creating memories, they have an easier time forgetting too.   CA1 
pyramidal cells in aged animals have been shown to have an enhanced 
afterhyperpolarization (AHP) response (Landfield and Pitler, 1984; Moyer et al., 
 6 
 
1992) which usually diminishes in younger animals as a consequence of learning 
(for review see Wu et al., 2002).        
 Age-associated changes in CA3 have been less studied, but De Groot and 
Bierman (1987) did report a loss of synapses similar to that seen in the DG.  
Likewise, altered LTP characteristics comparable to those in the aged DG have 
been described in the aged CA3 following perforant path stimulation (Dieguez 
and Barea-Rodriguez, 2004).           
 Calcium regulation also significantly affects synaptic function.   Based 
upon electrophysiological studies of Ca2+-dependent neuronal processes,  
important biomarkers for aging in the hippocampus include increased L-type 
voltage gated Ca2+ channel (L-VGCC) activity (Thibault and Landfield, 1996), 
elevated Ca2+ transients (Thibault et al., 2001; Hemond and Jaffe, 2005) and the 
previously described enhanced AHP response and the corresponding impaired 
synaptic plasticity.  Patrylo et al. (1994) has pointed out that elevated Ca2+ could 
create ion disturbances (i.e. K+) leading to synchronized neuronal bursting, which 
may affect epileptogenic mechanisms in the aged hippocampus.  It is also 
important to note that disrupted Ca2+ homeostasis has long been known to be 
centrally involved in NMDA receptor-mediated excitotoxicity (reviewed by Lipton, 
2004).  
 Finally, neuroinflammation in the aged hippocampus must be discussed.  
The hippocampus is rich in glucocorticoid receptors (McEwen, 1996).  
Glucocorticoid exposure is linked to structural and functional changes in the 
hippocampus including decreased neuronal density, altered synaptic plasticity 
and deficits in spatial learning, all of which are ultimately associated with aging 
(for review see Landfield and Eldridge, 1994).  However, the relationship 
between glucocorticoids and aging is not as straightforward as once believed 
(Landfield et al., 2007).  Efficacy of glucocorticoid actions during aging are 
believed to be different for neurons and glia.  For example, glia are thought to 
lose sensitivity to glucocorticoids.  Therefore, normally suppressed inflammatory 
pathways are actually increased during aging (Landfield et al., 2007).  
Convincing evidence that neuroinflammatory changes (increases in 
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proinflammatory cytokines and microglial activation) do occur in the hippocampus 
during aging, and are accompanied by deficits in LTP, has been reported by 
Griffin et al. (2006).   
    
Glutamate Neurotransmission in the Young and Aged Hippocampus 
  
 Glutamate release and clearance are the key determiners of 
neurotransmitter availability for participation in receptor-dependent processes. 
Though release from depolarized nerve terminals in a Ca2+-dependent manner is 
the predominant mechanism of glutamate release into the extracellular space, 
astroglia have been shown to release glutamate as well (Bezzi et al., 1998; 
Volterra and Steinhäuser, 2004).  Astroglia also indirectly modulate glutamate 
release into the extracellular space via their most well known function, glutamate 
clearance with high affinity transporters, by controlling the ability of extrasynaptic 
glutamate to activate presynaptic mGluRs which feedback to adjust neuronal 
glutamate release (Huang and Bergles, 2004).  As reviewed by Danbolt (2001); 
ionotropic and metabotropic glutamate receptors are widely distributed 
(dendrites, nerve terminals, neuronal cell bodies and glial cells), so to avoid 
improper activation of these receptors, extracellular glutamate levels must be 
highly regulated.  The only way to remove glutamate from the extracellular 
space, regardless of the release mechanism, is through high affinity transporters 
located mainly on astroglia (Gegelashvili and Schousboe, 1998) (Figure 1.2).     
 As outlined earlier, much is known about age-associated changes in 
hippocampal synapse numbers, electrophysiological characteristics and 
plasticity.  A reduction in hippocampal ionotropic glutamate receptors and their 
constituent subunits with age has been correlated with decline in memory 
function (Magnusson, 1998; Adams et al., 2001; Tang et al., 2001; Clayton et al., 
2002).  A similar correlation exists with memory impairment and reduced levels of 
the vesicle protein synaptophysin (Smith et al., 2000).  Hippocampal aging is also 
associated with activated gliosis evidenced by increased GFAP staining, 
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increased astrocytic size and fibrosis (Vaughan and Peters, 1974; Landfield et 
al., 1977) and a complete loss of organization in astrocytic processes (Sykova, 
1998).  Changes in glia can possibly alter the expression and function of high 
affinity transporters and change glutamate levels in the extracellular space.  Also, 
learning and memory deficits are associated with alterations in gamma-
aminobutyric acid (GABA) neurotransmission associated with hippocampal 
interneurons that regulate excitatory transmission from principle cells (Shetty and 
Turner, 1998; Vela et al, 2003).  Specifically, a loss of GABAergic neurons (but 
not synapses) has been reported in CA1, but not CA3 or the DG, with aging (Shi 
et al., 2004).  Collectively, these data indicate that alterations in glutamatergic 
neurotransmission occur in the hippocampus during aging, but extensive 
investigations of glutamate release and clearance processes have only 
succeeded in filling the literature with contradicting reports (Segovia et al., 2001).    
 The majority of studies investigating regulation of glutamatergic 
neurotransmission during aging have used ex vivo experimental methodology 
(i.e. tissue homogenates, slices and synaptosomes).  Total hippocampal content 
of glutamate has been shown to decrease (Banay-Schwartz et al., 1989) or not 
change (Wallace and Dawson, 1990) in aged compared to young animals.  Basal 
extracellular glutamate levels in aged animals have been reported to decrease 
(Saransaari and Oja, 1995), increase (Freeman and Gibson, 1987) or not change 
(Meldrum et al., 1992) compared to young animals.  Similarly, an age-associated 
increase (Meldrum et al., 1992; Saransaari and Oja, 1995) and decrease 
(Freeman and Gibson, 1987) have been reported for stimulus-evoked glutamate 
release, while no change has been reported in glutamate clearance when 
comparing young and aged animals (Gilad et al., 1990; Najerahim et al., 1990; 
Palmer et al., 1994).   Isolating the hippocampus from its extrinsic neuronal 
connections and disrupting the intrinsic connections could account for the 
inconsistency in previous aging studies using ex vivo methods.        
 Only two prior studies have attempted to characterize in vivo glutamate 
regulation in the hippocampus of aging animals.  Using microdialysis, Massieu 
and Tapia (1997) showed an increase in tonic hippocampal glutamate in aged 
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compared to young rats, and Zhang et al. (1991) reported a decrease.  Though 
microdialysis does allow for in vivo measurements of tonic glutamate (i.e. steady-
state glutamate concentration in the extracellular space), the slow temporal 
resolution limits the ability to investigate the rapid release and clearance 
dynamics associated with glutamate neurotransmission (Timmerman and 
Westerink, 1997; Danbolt, 2001).  This is important because alterations in 
release and/or clearance may not manifest with changes in basal glutamate 
levels due to biological compensation, and therefore must be studied directly.   
 
Animal Models of Status Epilepticus 
 
 The elderly population is the fastest growing age group in the United 
States (Collins et al., 1997).  Studies over the last 20 years have established that 
the elderly population has an increased risk for status epilepticus (SE), status-
related morbidity and mortality (DeLorenzo et al., 1992), and experiences the 
highest incidence of epilepsy in the population (Luhdorf et al., 1986; de la Court 
et al., 1996).  SE is defined as continuous seizure activity persisting for more 
than 5-10 minutes, or 2 or more seizures without full recovery of neurologic 
function in between (Treiman et al., 1998; Lowenstein et al., 1999).  Despite the 
obvious importance of understanding epilepsy in the elderly, especially SE, very 
few basic science studies have modeled epilepsy in aged animals (Leppik et al., 
2006). 
 Chemically induced SE models typically use high doses of a convulsive 
agent (e.g. kainate, pilocarpine, 4-aminopyridine) administered systemically.   
These agents can also be applied intrahippocampally (Mathern et al., 1993; 
Fragoso-Veloz et al., 1990).  Sustained electrical stimulation to the perforant path 
(Sloviter, 1987) and ventral hippocampus (Lothman et al., 1990) can also induce 
SE, though these models are less utilized.  In all models animals display acute 
behavior and EEG activity consistent with clinical SE, and if allowed to continue 
for a sufficient duration will develop hippocampal neuronal damage, also 
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observed in humans (reviewed by Morimoto et al. 2004).  After a variable lapse 
of time, animals will develop spontaneous seizures, and as pointed out by 
Morimoto et al. (2004), most researchers are interested in the development of 
this pathology and symptomatology similar to that seen in human temporal lobe 
epilepsy (TLE) following SE, and not the SE event itself.   
 Pilocarpine-induced SE is a commonly used animal model.  Pilocarpine 
induces SE through M1 muscarinic receptor activation (Hamilton et al., 1997), but 
seizures are maintained by NMDAR activation (Nagao et al., 1996) and 
accompanied by increases in hippocampal glutamate (Smolders et al., 1997).  
Pilocarpine produces loss of hippocampal neurons and synaptic reorganization 
via mossy fiber sprouting (Mello et al., 1993).  Historically, mortality rates have 
been high (at least 30-40%, Cavalheiro et al., 1991).  Even though administering 
multiple low doses or using diazepam to limit the SE duration have improved 
mortality rates (for review see Curia et al., 2008), no examples of SE modeling in 
aged animals using pilocarpine exist in the literature.  
 Status epilepticus has been modeled in aged rats using a repeated low-
dose (2.5 mg/kg per hour) kainic acid protocol (Darbin et al., 2004).  This study 
showed that aged animals (22-25 months old) had a significantly shorter latency 
to seizure behavior compared to young rats (7 months) and significantly more 
wet-dog shakes, classified in this study as pre-seizure behavior.  Likewise, aged 
rats also displayed altered electroencephalograms (reduction in higher 
frequencies) compared to young rats.  As with pilocarpine, kainic acid treatments 
cause mossy fiber sprouting and also neuronal loss in CA3 (Leite et al., 1996). 
 
Glutamate and Seizures 
 
 As previously mentioned, researchers have traditionally been more 
focused on the resultant TLE following SE modeling, rather than the SE event.  
An extensive relationship between glutamate dysregulation and TLE has been 
documented in the literature which can offer some insight into potential 
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mechanisms of glutamate dysregulation during and following SE that may 
ultimately lead to recurrent unprovoked seizures, especially in the elderly 
population.    
 From studies sing microdialysis in human TLE patients, extracellular 
glutamate has been shown to increase 30-fold above normal basal levels during 
seizure, and persist at levels approximately 12-fold higher than normal for at 
least 20 minutes after the cessation of seizure activity (During and Spencer et al., 
1993).  Glutamate levels are also elevated during interictal periods in 
epileptogenic hippocampi (Cavus et al., 2005).  Indicating a universal 
involvement of glutamate in seizures, increases in glutamate have also been 
shown with microdialysis in rodent kainic acid models (Ueda et al., 2002) and 
pilocarpine models (Meurs et al., 2007) of epilepsy during the initial SE. 
 The very important involvement of astroglia in regulating extracellular 
glutamate concentrations has already been described.  The predominant 
hippocampal excitatory amino acid transporter (EAAT2 or GLT-1; Rothstein et 
al., 1994) has been reported to be decreased in patients with TLE and 
accompanying hippocampal sclerosis (gliosis) (Mathern et al., 1999; Proper et 
al., 2002).  This could alter clearance of extracellular glutamate and possibly 
contribute to the onset or propagation of epileptoform activity.     
 Astroglia are also responsible for metabolism of glutamate via the enzyme 
glutamine synthetase (GS), which converts glutamate recovered from the 
extracellular space to glutamine.  Glutamine is then shuttled back to neurons, 
where it is converted back to glutamate, and packaged in synaptic vesicles for 
release (Figure 1.2).  Patients with TLE have been shown to be severely deficient 
in GS (Eid et al., 2004).  It is necessary to point out that GS activity has also 
been shown to be significantly decreased in the cortex during aging (Smith et al., 
1991); though decreases in GS have not been shown in the aged hippocampus 
(Goss et al., 1991; Wu et al., 2005).  Efficient glutamate clearance by astroglia 
may be compromised due to diminished metabolism from changes in GS, 
ultimately resulting in increased extracellular levels (Eid et al., 2008) which could 
lead to seizure or excitotoxicity. 
 12 
 
 Likewise, astroglia are important for the maintenance of extracellular K+ 
levels which can also affect neuronal excitability.  Buffering of extracellular K+ via 
reuptake is thought to be primarily achieved with inward rectifying K+ (Kir) 
channels in certain glial cell types (Newman, 1993).  Several studies have shown 
a down regulation of Kir currents in patients with TLE (Bordey and Sontheimer, 
1998; Hinterkeuser et al., 2000; Schroder et al., 2000).  It is believed that 
diminished K+ buffering from dysfunction of Kir channels may contribute to 
hyperexcitability in epileptic tissue (Steinhauser and Seifert, 2002).  It should also 
be noted that pro-inflammatory cytokines are shown to transiently increase in 
experimental models of TLE.  One cytokine, IL-1 β, has been shown to regulate 
astrocytic phenotype and stimulate Ca2+ -dependent glutamate release, which 
may trigger and maintain seizures (reviewed by de Lanerolle and  Lee, 2005).         
 The common practice of temporal lobe resection as treatment for 
refractory TLE has allowed unique in vitro studies with human tissue.  This has 
provided a large body of knowledge about potential mechanisms of excitatory 
neurotransmission dysregulation, including the changes in astrocytes outlined 
above.  However, lacking in this cohort of patients, as is lacking in the basic 
science literature, is a representation of the elderly epileptic population (Leppik et 
al., 2006).  Knowing that elderly patients are particularly affected by epilepsy and 
SE, but sometimes poor surgical candidates, makes the utilization of models 
especially important for understanding the pathology and unique treatment 
demands in the aged  population.  Though microdialysis has provided a 
correlation between increased extracellular glutamate and seizure, the temporal 
resolution of microdialysis limits the ability to measure alterations in the fast 
aspects of glutamate neurotransmission like release and clearance.  A clear 
need exists for in vivo characterization of dynamic glutamatergic 
neurotransmission during status epilepticus, which may provide novel information 
about the role of glutamate in the aggressive clinical course of seizure disorders 
in the elderly (During and Spencer et al., 1993; Cavus et al., 2005).  
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Thesis Outline 
 
 For the work presented in this dissertation, it was especially important to 
consider the similarity in substrates for age-associated and seizure-associated 
changes in the hippocampus (i.e. glutamate neurotransmission, astrocytes).  
Chapter Two provides a detailed description of the materials, instrumentation, 
methodology and statistical analysis used for all dissertation experiments.  In 
Chapter Three, ceramic enzyme-based microelectrode arrays (MEAs) were used 
for second-by-second measurements of glutamate neurotransmission in the 
discrete dentate gyrus (DG), cornu ammonis 3 (CA3) and cornu ammonis 1 
(CA1) trisynaptic subregions.  These experiments investigated the capacity of 
glutamate release and uptake in anesthetized young (3-6 months), late-middle 
aged (18 months) and aged (24 months) Fischer 344 (F344) rats. Potassium-
evoked release of glutamate was greatest in the DG of late-middle aged rats as 
compared to young and aged animals.  The most fascinating finding was that the 
CA3 subregion exhibited profound dysregulation during aging.  CA3 had 
diminished evoked glutamate release in aged rats compared to young and late-
middle aged animals.  Also, alterations within the trisynaptic circuit during aging 
showed a significant loss of glutamate release capacity in CA3 and CA1 
compared to the DG in both late-middle aged and aged rats.  These findings 
suggest an altered function or competence of the glutamate fibers in aging 
animals.  Finally, the aged DG showed a significantly increased glutamate uptake 
rate compared to the DG of young animals, suggesting that the increases in 
glutamate release in late-middle aged rats may result in compensatory increases 
in glutamate uptake capacity in aged rats. These data are the first to provide 
insight into age-related changes in functional glutamatergic neurotransmission in 
subregions of the rat hippocampus.    
 Chapter Four further explores glutamate regulation using MEAs adapted 
for use in unanesthetized animals. In summary, these studies were designed to 
investigate glutamate regulation in the hippocampus during normal aging, and to 
elucidate the potential relationship between glutamate dysregulation and rigor of 
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status epilepticus (SE) in aging populations.  Tonic glutamate was shown to be 
significantly elevated in the hippocampal formation of late-middle aged and aged 
rats compared to young rats prior to SE modeling. The quantification and 
characterization of spontaneous and highly synchronized glutamatergic release 
events that co-manifested with the appearance of SE behavior provided a novel 
means to link glutamate dysregulation with seizure pathology.  Pre-SE tonic 
glutamate significantly correlated with the severity of SE after low doses of 4-AP, 
as animals with the highest tonic levels experienced the most persistent and 
severe behavior, along with the largest amount of spontaneous glutamate 
release.  Regardless of pre-SE tonic glutamate levels, after the high dose of 4-
AP significantly longer SE durations and more spontaneous glutamate release 
activity was observed in aged animals.  Taken together, these results indicate 
that a strong relationship exists between aberrant glutamate neurotransmission 
and SE, and support an etiological role for age-associated glutamate 
dysregulation in seizure disorders occurring with disproportionately high 
frequency and severity in elderly populations.  
 Chapter Five chronicles the development and testing of microelectrodes 
for future clinical uses.  These studies demonstrated that we can obtain real-time 
measurements of extracellular glutamate in awake non-human primates using 
enzyme-based MEA technology coupled to amperometric recordings with a 
design that has been adapted for human use (Spencer-Gerhardt-2 MEA (SG-2)).  
The temporal resolution (2 Hz) of these measurements allowed us to record 
dynamic oscillations in extracellular glutamate, which to our knowledge has never 
been reported.  We showed that sterilization did not significantly compromise the 
integrity and function of the enzyme/protein layers applied to SG-2 MEAs for the 
detection of glutamate.  We also showed that the SG-2 MEAs have a shelf-life of 
close to a year.     
   
Copyright © Michelle Lee Stephens 2009 
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Figure 1.1 The Trisynaptic Pathway 
The trisynaptic pathway or circuit is the unidirectional flow of excitatory 
glutamatergic neurotransmission through the hippocampal formation.   Synapse 
1 is at the terminal end of perforant path projections from the entorhinal cortex 
(EC) to the granule cells of the dentate gyrus (DG); synapse 2 is at the end of 
DG mossy fiber projections to pyramidal cells in cornu ammonis 3 (CA3) and 
synapse 3 is at the end of CA3 Schaffer collateral projections to pyramidal cells 
in cornu ammonis 1 (CA1).   
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Figure 1.2 Typical Glutamate Synapse in the Trisynaptic Pathway 
 
Excitatory post-synaptic potentials (EPSPs) are generated when glutamate is 
released from presynaptic vesicles and subsequently binds to receptors located 
on the postsynaptic membrane (mGluR, KainateR, NMDAR, AMPAR).  
Astrocytes express high-affinity transporters that function to remove glutamate 
from the extracellular space and terminate glutamatergic neurotransmission.  
Glutamate that is not recovered can diffuse to presynaptic mGluRs and auto-
regulate glutamate release.  Astrocytes are also important for buffering 
extracellular potassium via inward rectifying K+ channels.  Once recovered by 
glia, glutamate is converted to glutamine, shuttled across the extracellular space 
and reconverted to glutamate in presynaptic terminals where it is packaged for 
vesicular release.   
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Chapter Two: Materials and Methods 
 
The Fischer-344 Rat as a Model of Human Aging 
 
 Rodent models have a long history of contributing to the scientific study of 
aging.  Inbred strains have been particularly utilized because their genetic 
uniformity helps minimize sample sizes.  Freedom from genetic variables also 
facilitates the isolation of aging effects on the data.  Currently the National 
Institute on Aging maintains several inbred colonies for aging research including 
Fischer-344 (F344) and Brown-Norway (BN) rats and BALB/cBy, CBA, C57BL/6 
and DBA/2 mice.  Studies using F344 rats to model mammalian aging are the 
most numerous in the aging literature.  Though the repeated use of F344 rats 
has brought criticism from some researchers with concerns that scientists are 
limiting the scope of our knowledge about aging (Weindruch and Masoro, 1991), 
the novelty of the studies and research techniques presented in this dissertation 
prompted us to choose the F344 strain because we felt the abundant body of 
prior work would assist in the interpretation of our data.  Both male and female 
F344 rats are utilized for aging studies, but we chose to work with males to avoid 
the effects of hormonal fluctuations with age that can affect the hippocampal 
formation (reviewed by Foy et al., 2008).  
 A concern for researchers working with aged animals is the incidence of 
age-associated disease that may influence studies.  Male F344 rats do 
commonly display glomerulonephropathy and testicular interstitial cell tumors at 
advanced ages, but a comprehensive examination showed that the male F344 
rats displayed less of 10 other age-associated lesions than the other available 
inbred strain, BN rats (Holmes, 2003).   
 F344 rats have a typical life-span of approximately 27 months (Coleman et 
al., 1977).  Though average life-span does vary across different strains, it has 
been agreed upon that a rat is considered aged at 22 months (Masoro, 1990).  
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For our studies characterizing the effects of aging on glutamate 
neurotransmission in the normal and actively seizing hippocampus, three age 
groups were chosen: young (3-6 months), late-middle aged (18 months) and 
aged (24 months).  Using the conversion of ‘1 rat month = 3 human years’, these 
age groups simulate humans of approximately 18, 54 and 72 years old.  It is 
important to note that the youngest group is reproductively mature so these 
studies were not confounded by development.  Approximately two-thirds of aged 
F344 rats are found to be impaired during memory tasks (reviewed by Geinisman 
et al., 1995), so we conclude that our aging model was a good choice for 
studying glutamatergic regulation in a functionally heterogeneous sample, 
representative of the aging human population. 
 
The 4-aminopyridine Status Epilepticus Model 
  
 4-Aminopyridine (4-AP), a K+ channel blocker, has been used extensively 
to model in vitro seizure activity (Perreault and Avoli, 1991 among many others), 
but much less in vivo research has been conducted.  Interest in the 4-AP 
compound originated from its ability to prolong action potentials and increase 
neurotransmission, resulting in the use of 4-AP for the treatment of neurological 
disorders such as spinal cord injury (Cardenas et al., 2007).  It was learned that 
over-exposure in humans caused convulsions and subsequently 4-AP became a 
compound of interest for epilepsy research (Spyker et. al., 1980).   
 4-AP produces limbic seizures when microinjected (Fragoso-Veloz, et al., 
1990; Morales-Villagran et al., 2008) or applied with reverse microdialysis (Pena 
and Tapia, 1999; Media-Ceja et al., 2000; Pena and Tapia; 2000; Ayala and 
Tapia, 2005) into the hippocampal formation in vivo.  Following a single dose of 
4-AP, local seizure induction is rapid (< 1 minute for application into CA1, 4.2 
nmol, Fragoso-Veloz, et al., 1990; ~10 min. for EC application, 10 nmol, Morales-
Villagran et al., 2008), followed by propagation to other brain areas including the 
contralateral hippocampus and eventually the cortex.  Animals display behaviors 
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characteristic of limbic seizures and analogous to those seen with kainic acid 
administration (Ben-Ari et al., 1981) including wet-dog shakes, oral automatisms 
and grooming.  Microdialysis studies have shown that glutamate levels rise in the 
hippocampus during 4-AP-induced status epilepticus (SE), but slow sampling 
rates on the order of minutes have allowed for nothing more detailed than the 
basic conclusion that extracellular glutamate transiently increases to a maximum 
of 6-8 µM then returns to baseline (~2 µM) over the course of an hour or so 
(Pena and Tapia, 1999; Media-Ceja et al., 2000; Pena and Tapia; 2000; Ayala 
and Tapia, 2005).  4-AP also induces NMDAR-dependent neurotoxicity (Pena 
and Tapia; 2000; Ayala and Tapia, 2005) similar to that seen in kainic acid 
models (Brandt et al., 2003), so dysregulation of glutamate neurotransmission 
during SE needs to be more extensively studied.  
 We believe 4-AP-induced SE was the most appropriate and practical 
model for our research.  In addition to inducing glutamate release which mimics 
numerous microdialysis recordings in seizure-prone humans and animal models 
of epilepsy, 4-AP blocks K+ currents (neuronal and glial).  A large body of work 
implicates 4-AP-sensitive K+ currents in the modulation of high frequency 
neuronal discharges (reviewed by Bordey and Sontheimer, 1999), but most 
important for our studies is the ability of 4-AP to block glial Kir currents (Bordey 
and Sontheimer, 1999) in accordance with glial data collected from the 
hippocampi of TLE patients (see Chapter 1).  The aged hippocampus 
experiences profound changes in glia, but the functional outcomes of these 
alterations are not known and may provide a critical link between age-associated 
hippocampal dysfunctional and the propensity for increased SE and negative 
outcomes.  We feel other models of SE (i.e. kainic acid) do not adequately 
incorporate means to exploit potential alterations in glial function within the aging 
hippocampus as it relates to the manifestation of SE.   
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Animals 
F344 Rat Studies 
 Young adult (3-6 months, n = 40), late-middle aged (18 months, n = 34) 
and aged (24 months, n = 42) male F344 rats were obtained from the National 
Institute on Aging colony (Harlan Sprague Dawley, Inc., Indianapolis, IN) and 
used for all experiments studying glutamate in the hippocampal trisynaptic circuit.  
Protocols for animal use were approved by the Institutional Animal Care and Use 
Committee.  In accordance with approved guidelines, animals were housed in a 
12 hour alternating light/dark cycle, with food and water available ad libitum.  All 
glutamate measurements were obtained during the ‘light phase’ and on average 
were recorded at 1:00 PM (EST).  These studies were focused on changes in 
glutamate regulation during ‘normal aging’, therefore animals were not enriched.   
 
Non-human primates 
 Three adult female rhesus monkeys (Macaca mulatta) were obtained from 
a commercial supplier (Covance, Alice, TX) (NHP 1 = 11 years old, NHP 2 = 19 
years old; NHP 3 = 21 years old).  Protocols for animal use were approved by the 
Institutional Animal Care and Use Committee.  Animals were housed in the 
Laboratory Animal Facilities at the University of Kentucky which is accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALACI).  Food and water were available ad libitum. All 
glutamate measurements were performed while the animals were awake during 
the ‘light phase’ of their 12 h light: 12 h dark maintenance schedule.  
 
Principles of Electrochemistry 
  
 The recording surface or ‘working-electrode’ of the microelectrode array 
(MEA) is an inert metal (platinum) that can oxidize or reduce compounds of 
interest when a potential is applied versus a Ag/AgCl reference electrode in ionic 
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contact with the MEA.  Computer-controlled low noise ‘patch clamp-like’ 
potentiostats with custom multiple-input recording software allow simultaneous 
measurements from several recording surfaces on a single MEA.  The 
potentiostat, or ‘headstage’, creates the required difference in potential between 
the MEA and the Ag/AgCl reference electrode, and measures the currents 
created by electrochemical reactions.  Applying a constant fixed potential to the 
microelectrode, known as amperometry, is one of the most straight-forward 
electrochemical techniques (Gerhardt and Burmeister, 2000).  If the potential is 
sufficient, a molecule at the surface of the working-electrode may donate 
electrons (oxidize) or accept electrons (reduce), both Faradaic chemical 
reactions that generate current which is linear with respect to the concentration of 
electroactive molecules.  Amperometry minimizes measurement of non-faradaic 
background current by the microelectrode, offering highly sensitive 
measurements of electrochemically active molecules.  This technique also allows 
for rapid sampling rates (ms to sec), providing a fast means to monitor 
neurochemistry of the extracellular space in real-time (Gerhardt and Burmeister, 
2000  
 Several neurochemicals of interest in the extracellular space are 
electrochemically active at a working electrode including dopamine (DA), 
norepinephrine, serotonin, nitric oxide, uric acid, and 3,4-dihyroxyphenylacetic 
acid (DOPAC).  Most of these molecules can also be easily shielded from the 
recording surfaces of the MEA by application of selective coatings (Hascup et al., 
2007).  To expand the repertoire of detectable neurochemicals, the recording 
sites can be coated with a variety of oxidase enzymes which convert 
electrochemically inactive analytes of interest to ‘reporter’ molecules of hydrogen 
peroxide (Gerhardt and Burmeister, 2000).  Applying a potential of +0.7 V vs. a 
Ag/AgCl reference is sufficient to oxidize hydrogen peroxide at the working sites.  
Current created by liberation of electrons during the oxidation of hydrogen 
peroxide is linear with respect to local concentration of the original enzymatic 
substrate. 
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Microelectrode Fabrication  
  
 MEAs used for the studies presented in this dissertation were constructed 
in conjunction with Thin Films Technology, Inc. (Buellton, CA).  Details of the 
fabrication process are outlined in Burmeister et al. (2001).  The multisite MEAs 
were mass fabricated using photolithographic methods.  Photolithography helps 
decrease overall production costs as multiple MEAs can be fabricated with 
minimal waste of starting materials.  Cost is an ever-present concern for research 
instrumentation, as well as for clinical diagnostic and treatment technologies.  
Arrays of platinum recording surfaces were patterned onto a ceramic substrate 
(Coors Superstrate 996 (alumina, Al2O3) Coors Ceramics, Golden, CO) which 
provides a strong non-flexible base for precise stereotactic placement, minimizes 
cross-talk noise between platinum recording sites, and can be polished to 
achieve excellent biocompatibility in chronic implants (Rutherford et al., 2007).  
The ceramic substrate was modified depending on the desired application (i.e. 
anesthetized or unanesthetized animal recordings; acute or chronic animal 
recordings).  Extensive research and development of the MEA fabrication and 
cleaning processes have produced very deliberate protocols for the construction 
of durable and reusable MEAs (for review see Hascup et al., 2007). 
 For the in vivo studies presented here, the S2 MEA configuration was 
selected (Figure 2.1).  The S2 has four platinum recording surfaces, each 15 x 
333 µm.  The platinum sites are arranged in two pairs, stacked in a dorsal-ventral 
orientation with 100 µm spacing between pairs and 30 µm spacing between sites 
within each pair.  The intention of this design is to selectively configure one 
recording pair with glutamate oxidase (GluOX) for glutamate detection via 
production of the reporter molecule hydrogen peroxide and the other pair with 
non-active protein for self-referenced comparison (Burmeister and Gerhardt, 
2001).  For all calibrations and animal studies presented here, the Fast Analytical 
Sensing Technology system (FAST-16/mark II, Quanteon L.L.C, Nicholasville, 
KY) was used to perform constant voltage amperometry (+0.7 V vs. Ag/AgCl 
reference electrode).   
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Microelectrode Preparation for In Vivo Glutamate Measurements 
Measurements in Anesthetized Rats 
 All S2 platinum recording surfaces were electroplated with meta-
phenylenediamine (5 mM, Acros Organics, New Jersey, USA), which creates a 
molecular size exclusion layer blocking electrochemically active interferents such 
as DA, DOPAC and ascorbic acid based upon their size.  The MEAs were 
configured for selective glutamate detection as per our previously published 
methods (Burmeister et al., 2002; Pomerleau et al., 2003, Day et al., 2006; 
Hascup et al., 2006).  Briefly, the ventral pair of platinum recording surfaces were 
manually coated with  approximately 1 µL of enzyme solution (1% bovine serum 
albumin, 0.125% glutaraldehyde, and 1% GluOX) which configured these sites 
for glutamate detection through the enzymatic conversion of glutamate to H2O2.  
The dorsal pair of platinum sites was coated with a similar BSA/glutaraldehyde 
solution lacking the glutamate oxidase enzyme.  These sites are referred to as 
‘sentinel’ (Figure 2.1).    
 A pre-pulled single-barrel micropipette (1 mm o.d., 0.58 mm i.d. glass, A-
M Systems Inc., Everett, WA) was attached to each ceramic MEA substrate with 
Sticky Wax (Kerr Lab Corporation, Orange, CA). This allowed for intracranial 
application of a KCl solution to study stimulus-evoked glutamate release or an 
exogenous glutamate solution to study glutamate clearance.   The tips of the 
micropipettes were pulled to an inner diameter of 10 µm, and positioned 70 ± 20 
µm away from the microelectrode surface, centered in the 100 µm space 
between the dorsal and ventral platinum recording pairs (Figure 2.2).   
Measurements in Unanesthetized Rats 
 All S2 platinum recording surfaces were coated with Nafion and dried at 
175°C for 4 minutes.  Nafion repels electrochemically active anionic interferents 
such as DOPAC and ascorbic acid (Gerhardt et al., 1984).  Based upon empirical 
data, Nafion is considered more stable than meta-phenylenediamine in vivo, 
warranting its use in all studies with unanesthetized animals.  The MEAs were 
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configured for selective glutamate detection as per our previously published 
methods (Burmeister et al., 2002; Pomerleau et al., 2003, Day et al., 2006; 
Hascup et al., 2006) (Figure 2.1).   
 The ceramic substrate of the MEA used for studies in anesthetized rats, 
referred to as the paddle, was modified for chronic implantation which allowed 
glutamate measurements in unanesthetized rats.  A detailed construction 
protocol has been previously published (Rutherford et al., 2007).  Briefly, the 
ceramic MEA paddle was shortened and configured with an electrical connection 
for each platinum S2 recording site and attached to a miniature connector 
(Ginder Scientific, Ottawa, Ontario).  A miniature a Ag/AgCl wire reference 
electrode was also attached to the connector.  All electrical connections were 
covered with epoxy.  For local delivery of solutions, a 26-gauge stainless steel 
guide cannula (Plastics One, Roanoke, VA, USA) was attached to the ceramic 
paddle with sticky wax (Kerr Corp., Orange, CA, USA) and positioned to allow 
solution application to the microenvironment between all four platinum recording 
sites through an inserted internal cannula.  The distance between the internal 
cannula and the recordings sites was approximately 50 µm. A fixed stainless 
steel dummy cannula remained in the guide whenever the animal was not 
receiving solutions.  The completed assembly containing the ceramic paddle, 
miniature connector and guide cannula is referred to as the rat pedestal 
(Rutherford et al., 2007) (Figure 2.2). 
Measurements in Unanesthetized NHPs (Spencer-Gerhardt-2 MEA) 
 The Spencer-Gerhardt-2 microelectrode array (SG-2, Figure 2.3) was 
modeled after the clinically utilized SPENCER Probe Depth Electrodes 
(ADTECH, Racine, Wisconsin).  The S2 configuration previously designed for 
basic science MEAs was conserved in the design of the SG-2 for comparisons of 
measures in rodents and non-human primates (Day et al., 2006; Nickell et al., 
2005; Nickell et al., 2007; Pomerleau et al., 2003; Quintero et al., 2007) and 
eventually humans.  Fabrication of the SG-2 was modified from the basic science 
MEA design to incorporate an extended flexible polyimide shaft for access to 
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ventral brain regions in primates.  All S2 platinum recording surfaces were coated 
with Nafion and dried at 175°C for 4 minutes.  The recording sites were 
configured for selective glutamate detection as per our previously published 
methods (Burmeister et al., 2002; Pomerleau et al., 2003, Day et al., 2006; 
Hascup et al., 2006) (Figure 2.1).       
In Vitro MEA Calibration 
 To correct for subtle inconsistencies in platinum deposition during 
photolithography and differences in thickness of manually applied coatings that 
may affect the efficiency of hydrogen peroxide oxidation, MEAs were calibrated 
prior to in vivo experimentation.   
 The platinum recording sites, and a glass Ag/AgCl reference electrode 
were submerged in phosphate-buffered saline (0.05 M, pH 7.4, 37°C) while serial 
aliquots of glutamate (20 mM) were added to yield final buffer glutamate 
concentrations of 20, 40 and 60 µM.  The resulting increase in current (pA) from 
oxidation of hydrogen peroxide was measured by the FAST-16 electrochemistry 
instrument.  Standard response curves were generated and used to equate a 
change in current from the oxidation of hydrogen peroxide with a proportional 
change in analyte concentration (Burmeister and Gerhardt, 2001).  The recording 
sites measured typical linear increases in current following serial glutamate 
additions (r2 > 0.99).  The slope of calibration curve is referred to as the 
microelectrode sensitivity to glutamate (pA/µM).  For each microelectrode the 
limit of detection (µM) was also determined (LOD = 3 times the baseline signal-
to-noise ratio). Microelectrodes were also exposed to an ascorbic acid (250 µM) 
challenge to determine the selectivity ratio (glutamate:AA) as an indication of 
effective blockade of electrochemical interferents.  Hydrogen peroxide was also 
added to the buffer as a positive control (Figure 2.4).   
 In vitro calibrations were also performed to determine the effects of 
sterilization on MEA function.  Of note is that unlike the basic science calibration 
protocol utilizing a glass Ag/AgCl reference electrode, we submerged a Ag/AgCl 
skin reference electrode (4 mm, shielded; World Precision Instruments Inc., 
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Sarasota, FL) directly into the calibration beaker with each SG-2. The Ag/AgCl 
skin reference electrodes can be sterilized, which will assist in development of a 
completely sterile SG-2 MEA calibration procedure for clinical use.   
SG-2 Sterilization Studies 
 All four platinum recording sites of the SG-2 MEAs were configured for the 
detection of glutamate by the application of enzyme (GluOX) and protein (BSA) 
solution (< 1 µL, 1% GluOX/ 1% BSA/ 0.125% glutaraldehyde) (Burmeister et al., 
2002).  To assess shelf-life, one batch of coated SG-2 MEAs were stored for 
approximately 11 months (n = 16) and one batch for one month (n = 16) at room 
temperature prior to electron beam sterilization.  Additional details of the 
sterilization procedure are proprietary. 
 
Confirmation of Electrode Placement 
Histological Evaluation (Rat Studies) 
 Upon completion of each anesthetized experiment, Fast Green dye 
(Sigma-Aldrich) was applied through the micropipette (500 nL) to mark the 
locations of the microelectrode.  Dye was not needed to mark the location of 
MEAs implanted chronically for studies in unanesthetized rats.  Animals were 
euthanized with isoflurane, the brains removed, frozen at -20C° and the positions 
of the microelectrode in the hippocampus verified by visual examination after 
slicing the brains (40 µm) on a cryostat (Figure 2.5). Data were excluded if there 
was clear indication that the MEA had missed the DG, CA3 or CA1 subregions of 
rat hippocampus (n = 5 for anesthetized studies; n = 4 for unanaesthetized). 
Anatomical MRI (NHP Studies) 
 SG-2 MEAs were targeted to the ventral putamen through a surgically 
implanted access cannula (Figure 2.3).  The brain coordinates for cannula 
implantation and subsequent MEA placement in the putamen were determined by 
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magnetic resonance imaging (MRI) before surgery, and confirmed post-
implantation (Figure 2.6).  
    
In Vivo Basal Glutamate Measurements 
  
 The most basic glutamate measurement obtained with MEAs is tonic, also 
called basal or resting, glutamate levels in the extracellular space.  Tonic 
glutamate levels were a parameter of interest for all experiments described in this 
dissertation.  Tonic glutamate levels are determined by the balance of glutamate 
release and clearance processes.  For all measurements of tonic glutamate, the 
current produced by oxidation of background electroactive substances in the 
extracellular space and the charging current of the electrode surface was 
removed from the current measured with the glutamate-sensitive recording sites 
by subtraction.  This is referred to as self-referencing and isolates the current 
generated by oxidation of hydrogen peroxide formed from the enzymatic 
breakdown of glutamate (Burmeister and Gerhardt, 2001; Day et al., 2006).  For 
all studies presented here, current (pA) obtained by self-referenced in vivo MEA 
recordings was divided by the microelectrode sensitivity (pA/µM) obtained during 
calibration and reported as concentration of basal glutamate (µM) (Quintero, et 
al. 2007) (Figure 2.7). 
 
In vivo Amperometric Recordings in Anesthetized Rats 
In Vitro Microelectrode Calibration Specifications 
 Microelectrodes had a selectivity ratio of at least 20:1 (95% ascorbic acid 
blockade), and a very linear response to the serial glutamate aliquots (r2>0.99).  
Average microelectrode calibration parameters for these experiments were as 
follows (n = 27, mean ± S.E.M.):  glutamate sensitivity: 6 ± 0.3 pA/µM; limit of 
detection: 0.8 ± 0.2 µM. 
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Surgical Procedures 
 Male F344 rats were anesthetized with urethane (1.25 mg/kg, i.p.) and 
placed in a stereotactic frame (David Kopf Instruments, Tujunga, CA).  A bilateral 
craniotomy was performed removing a window of bone between bregma and 
lambda to allow access to the hippocampal formation.  A miniature Ag/AgCl 
reference electrode (200 µm) was implanted into the right frontal cortex.  The 
micropipette/microelectrode assemblies (Figure 2.2) were targeted to the 
dendritic trees of hippocampal principal cells in the DG, CA3 and CA1 sub-
regions.  Stereotactic coordinates were adapted from Paxinos and Watson 
(2004) to account for changes in animal size and skull thickness with age.   
Anterior-posterior and medial-lateral coordinates were taken from bregma, and 
dorsal-ventral coordinates were taken from the top of the skull.  CA1 and CA3 
recordings were performed at the same AP and ML coordinates with the 
microelectrode at two different depths.  Placement coordinates were as follows: 
young (337 ± 50 g),  CA1{CA3}  AP: -(3.9-4.3), ML: ± 3.4-3.6, DV: -3.5 {-4.1}; DG 
AP: -4.1, ML ± 2.1, DV: -4.2; late-middle aged (452 ± 36 g), CA1{CA3}  AP: -(4.1-
4.5), ML: ± 3.7-3.9, DV: -3.9 {-4.5}; DG AP: -4.4, ML ± 2.2, DV: -4.5; aged (424 ± 
32 g), CA1{CA3}  AP: -(4.4-4.8), ML: ± 3.7-4.0, DV: -4.0 {-4.6}; DG AP: -4.6, ML 
± 2.4, DV: -4.6.   
 
Tonic and Phasic Glutamate Measurements 
 Basal glutamate measurements were obtained from each subregion 
following a baseline period of twenty minutes, prior to the application of any 
solutions. The order in which the subregions were targeted and in which 
solutions were applied was randomized during experimentation, so as to not bias 
the study by always targeting one particular area first.  A Picospritzer III (Parker 
Hannifin Corp. NJ, USA) was used to precisely control the volumes of KCl (70 
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mM KCl, 79 mM NaCl, 2.5 mM CaCl2, pH 7.4) or exogenous glutamate (100 µM 
in 0.9% physiological saline, pH 7.4) delivered during intracranial applications.    
 For KCl-evoked glutamate release, a dose response was performed in the 
hippocampal subregions to obtain the maximum glutamate release.  Volumes 
delivered ranged from 12.5-75 nL and were quantified using a microscope fitted 
with a calibrated reticule which determined the volume of drug ejected from the 
micropipette (Day et al., 2006).  Evoked glutamate release data were collected in 
young (n =11), late-middle aged (n = 8) and aged (n = 10) F344 rats.   
 For clearance studies, exogenous glutamate was locally applied in the 
hippocampal subregions (volumes ranging from 25-250 nL) to achieve a 
glutamate concentration in the microenvironment around the platinum recording 
sites within the range of concentrations most consistently obtained following KCl 
stimulation of glutamatergic terminals (10-20 µM, see Nickell et al., 2005).  This 
allowed us to study clearance of glutamate at physiologically relevant 
concentrations and offered the benefit of isolating glutamate clearance 
mechanisms, in contrast to studying glutamate clearance following KCl-evoked 
release which causes a non-selective release of neurotransmitters such as 
GABA.  This also allowed us to control for any effects of KCl on glia and 
glutamate transporters.  Glutamate clearance data were collected in young (n 
=16), late-middle aged (n = 13) and aged (n = 14) F344 rats. 
 
Data Analysis  
 Current (pA) obtained by self-referenced in vivo measurements in each 
hippocampal subregion was divided by the microelectrode sensitivity (pA/µM) 
obtained during calibration, and reported as concentration of tonic glutamate 
(µM) (Quintero, et al. 2007); young DG (n = 15), CA3 (n = 12), CA1 (n = 13); late-
middle aged DG (n = 6), CA3 (n = 11), CA1 (n = 10); aged DG (n = 16), CA3 (n = 
14), CA1 (n = 14).   
 Following local stimulation with 70 mM KCl in the DG, CA3, and CA1 
hippocampal subregions, the maximum increase in the glutamate signal from 
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baseline due to evoked glutamate release was recorded by the FAST software 
(pA).  Actual volumes delivered to obtain the maximum glutamate release were 
not significantly different across subregions or age groups (data not shown, two-
way ANOVA, p = 0.95).  Data were exported to a custom Excel spreadsheet for 
analysis.  Maximum increase in glutamate signal from baseline (pA) was divided 
by the microelectrode sensitivity (pA/µM) and reported as the maximum 
amplitude of evoked-glutamate release (µM). The first order rate of decay (k -1 
(sec-1)) was calculated for all evoked glutamate signals to examine the rate of 
return from maximum amplitude to baseline.  Based upon the known 
reproducibility of KCl-evoked glutamate signals in vivo (Nickell et al. 2005, Day et 
al. 2006), data from an individual subregion were only analyzed if at least three 
similar signals could be evoked, upon which the data were averaged and 
reported as a single number for that subregion: young DG (n = 8), CA3 (n = 6), 
CA1 (n = 6); late-middle aged DG (n = 5), CA3 (n = 5), CA1 (n = 7); aged DG (n 
= 6), CA3 (n = 5), CA1 (n = 5).   
 Following local application of 100 µM glutamate in the DG, CA3 and CA1 
hippocampal subregions, maximum increase in the glutamate signal from 
baseline was recorded by the FAST software.  Data were exported to a custom 
Excel spreadsheet for analysis where the maximum increase in glutamate 
signal from baseline (pA) was divided by the microelectrode sensitivity (pA/µM) to 
determine the amplitude of glutamate signal following local application of 
exogenous glutamate (µM).  Data from an individual subregion were only further 
analyzed if application of exogenous glutamate produced at least three signals in 
the range of 10-20 µM.  For signals in the defined range, the concentration of 
glutamate removed from the extracellular space per second was calculated using 
an Excel spreadsheet and reported as uptake rate (k -1 x maximum amplitude 
(µM/sec)). Data from individual subregions were averaged and reported as a 
single number for that subregion:  young DG (n = 9), CA3 (n = 7), CA1 (n = 11); 
late-middle aged DG (n = 7), CA3 (n =12), CA1 (n = 13); aged DG (n = 8), CA3 
(n = 6), CA1 (n = 8).   
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 A Grubb’s test for outliers removed two young animals and one aged 
animal from analysis.  Mean and SEM for all parameters of interest (tonic 
glutamate concentration, maximum amplitude of KCl-evoked glutamate signal 
and uptake rate following local exogenous glutamate application) were calculated 
for each subregion in each age group.  Due to the defined guidelines for inclusion 
of data in the analysis, not every animal produced a complete set of tonic 
glutamate levels, KCl-evoked glutamate release and glutamate uptake rate data 
in all three subregions.  Therefore, discrete comparisons were performed using a 
one-way analysis of variance (ANOVA, statistical significance defined as p<0.05) 
in GraphPad Prism 5 along with a Bartlett’s comparison of data variance to look 
for differences in the trisynaptic circuit within each age group and for differences 
within each subregion across age groups.  A Tukey-Kramer post-hoc test for 
unequal sample sizes was performed where necessary.   
 
In vivo Amperometric Recordings in Unanesthetized Rats 
MEA Calibration Specifications 
 Microelectrodes had a selectivity ratio of at least 20:1 (95% ascorbic acid 
blockade), and a linear response to the serial glutamate aliquots (r2>0.99).  The 
calibration parameters for the MEAs used in these experiments were (n = 55, 
mean ± S.E.M.): glutamate sensitivity: 5.4 ± 0.3 pA/µM; limit of detection: 0.42 ± 
0.05 µM.   
 
Surgical Procedures 
 One day before and the day of surgery, animals were given carprofen (15 
mg/kg i.p., Pfizer) to minimize pain.  Animals were placed in an induction 
chamber maintained with isoflurane (2% in O2) for the onset of anesthesia and 
then transferred to a stereotactic frame outfitted with a isoflurane nose cone for 
maintenance of anesthesia (2% isoflurane).  All procedures were performed in a 
Vertical Laminar Flow Workstation (Microzone Corp., Ottawa, ON, USA), with 
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sterile surgical instruments and dressings.  Standard precautions for preparation 
of the incision site were observed including fur removal and Betadine scrubbing.  
A craniotomy was performed to remove skull (3 mm2) and allow access of the S2 
recording sites to the hippocampus.  Stainless steel screws (Small Parts Inc., 
Miami Lakes, FL, USA) were anchored to the skull through three burr holes 
placed in areas away from the hippocampal access window (Rutherford et al., 
2007).  The Ag/AgCl reference electrode from the rat pedestal was placed into 
the left frontal cortex through a forth burr hole in the skull.  All implants were 
targeted to a specific subregion in the right hippocampus.  Anterior-posterior and 
medial-lateral coordinates for placement MEAs were taken from bregma, and 
dorsal-ventral coordinates were taken from the top of the skull:  young (350 ± 11 
g),  DG AP: -4.1, ML -2.1, DV: -4.0; CA3 AP: -4.1, ML -3.4, DV: -4.0; CA1 AP: -
4.1, ML: -2.4, DV: -3.3; late-middle aged (448 ± 5 g), DG AP: -4.3, ML -2.3, DV: -
4.4; CA3 AP: -4.3, ML ± 3.6, DV: -4.4; CA1 AP: -4.3, ML: -2.5, DV: -3.4; aged 
(435 ± 6 g), DG AP: -4.3, ML -2.3, DV: -4.5; CA3 AP: -4.3, ML: -3.6, DV: -4.5; 
CA1 AP: -4.3, ML: -2.5, DV: -3.5.  Dental acrylic (Lang Dental MFG, Wheeling, 
IL, USA) was applied to anchor the pedestal to the skull screws and fill the 
incision area.  The entire surgical procedure required approximately 1.5 hours of 
animal anesthesia.  Animals were allowed to recover two days before 
experimentation.  Maintenance doses of carprofen were given as needed during 
recovery.  The majority of animals tolerated the procedure, indicated by less than 
10% loss of body weight after surgery.  Only one animal (24 mo.) died from 
complications related to anesthesia.  No cases of infection were reported.   
 During experimentation, implanted pedestals were connected to a 
miniature 4-channel low noise headstage amplifier (‘rat hat’, Quanteon, LLC, 
Nicholasville, KY).   A locking AMS plug (Ginder Scientific) ensured secure 
attachment of the headstage amplifier to the rat pedestal, especially while 
animals were experiencing wet-dog-shakes characteristic of limbic seizures.  The 
amplifier was connected to the FAST16 mk II electrochemistry instrument via a 
low-torque commutator, allowing animals minimally inhibited movement around 
an observation box (Rutherford et al., 2007). 
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4-aminopyridine-induced Status Epilepticus (Intrahippocampal Injections) 
 A 20 mM solution of 4-AP (Fischer Scientific) was prepared in 
physiological saline (0.9%, pH 7.4).  On day 4 post-surgery, animals with CA1 
MEA implants received a low dose of 4-AP (5.25 µmol, 250 nL) followed by a 
high dose (21 µmol, 1 µL) injected locally through an internal cannula placed into 
the guide cannula on the rat pedestal (young n = 6; late-middle aged n = 6; aged 
n = 5).  All animals received the low dose of 4-AP first.  A period of 20 minutes 
was allowed between the end of low dose 4-AP-induced status epilepticus (SE) 
and the administration of the high dose.    
 
4-aminopyridine-induced Status Epilepticus (Behavioral Characterizations) 
 Intrahippocampal application of 4-AP produces behavior characteristic of 
limbic seizures including oral automatisms, grooming and paw tremor (Ben-Ari, 
1981).  The most evident limbic-associated behavior is wet-dog shaking 
(Fragoso-Veloz et al., 1990).  Starting from the point of 4-AP injection, wet-dog 
shakes (WDS) were tallied in five minute epochs.  For the purposes of these 
studies, the duration of SE was defined behaviorally.  The start of SE was 
identified by the first WDS.  Absence of WDS for an entire five minute epoch 
signaled the end of SE.  SE behavior self-terminated in all animals.   
 
Tonic and Phasic Glutamate Measurements 
 For tonic glutamate measurements, animals were acclimated to the 
observation box for 30 minutes and were then connected to the headstage 
amplifier.  Animals required 1 – 3 hours to reach a stable baseline.  Tonic 
glutamate measurements were obtained on days 3 and 4 post-surgery.  After 
tonic glutamate levels were determined, animals with CA1 MEA implants were 
administered 4-AP on day 4.  Dynamic fluctuations in extracellular glutamate 
were recorded on a second-by-second basis (1 Hz) during SE.  After SE, animals 
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were allowed to recover for one day.  On day 6, post-status basal glutamate 
levels were determined in a manner identical to days 3 and 4.   
 
Data Analysis 
 GraphPad Prism 5 was used for all statistical analysis.  For tonic 
glutamate measurements, current (pA) obtained by self-referenced in vivo 
measurements in each animal was divided by the microelectrode sensitivity 
(pA/µM) obtained during calibration (Quintero, et al. 2007) to determine 
concentration of basal glutamate (µM): young DG (n = 8), CA3 (n = 5), CA1 (n = 
6); late-middle aged DG (n = 6), CA3 (n = 5), CA1 (n = 6); aged DG (n = 24), 
CA3 (n = 6), CA1 (n = 6).  For all animals, tonic glutamate measurements 
obtained on days 3 and 4 were averaged and reported as a single value.  A 
Grubb’s test did not identify any significant outliers and all animals were included 
in the analysis.   Tonic glutamate levels in the DG, CA3, and CA1 hippocampal 
subregions were discretely compared across age groups using one-way analysis 
of variance tests (ANOVA, statistical significance defined as p < 0.05).  A Tukey-
Kramer post-hoc test for unequal sample sizes was performed where necessary.  
The combined data from all three subregions representing tonic glutamate in the 
hippocampal formation were also compared across age groups using an 
ANOVA.  A D-Agostino and Pearson omnibus normality test for Gaussian 
distribution was calculated for the combined hippocampal formation data.  For 
animals receiving 4-AP, pre-status basal glutamate (days 3 and 4 combined) was 
compared to post-status basal glutamate (day 6) using a two-way ANOVA for 
repeated measures (statistical significance defined as p < 0.05), followed by a 
Bonferroni post hoc test when necessary.     
 Duration of SE, average WDS/ 5 minute epoch and maximum WDS/ 5 
minute epoch was calculated for each animal following the low and high doses of 
4-AP.  All behavioral parameters were examined for dose and age-associated 
changes using a two-way ANOVA for repeated measures (statistical significance 
defined as p < 0.05) followed by a Bonferroni  post-hoc test when necessary.     
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 Custom MatLab-based software was used to identify and quantify 
spontaneous glutamate release events that occurred after 4-AP administration.  
A glutamate release event was defined as an increase in self-referenced current 
at least two-times the signal to noise ratio.  To further isolate spontaneous 
glutamate release, any artifact producing change in current that was occurring 
faster than once every 15 seconds and was not already removed by self-
referencing, was excluded.  The total number of glutamate release events 
occurring during the periods of defined SE was calculated for each animal.  Also, 
the latency to onset of spontaneous glutamate release events (min.), average 
magnitude of each release (peak size (µM)) and the average inter- event interval 
(release periodicity (sec.)) were determined for each animal.  The spontaneous 
glutamate release characteristics were examined for dose and age-associated 
effects using a two-way ANOVA for repeated measures (statistical significance 
defined as p < 0.05) followed by a Bonferroni post-hoc test when necessary.     
 To examine the relationship between pre-SE tonic glutamate 
concentration and the progression of the behavioral and glutamate release 
activities during SE, we calculated the linear regression line (slope = r2) for tonic 
glutamate (independent variable) verses 1) SE duration, 2) average WDS/ 5 
min., 3) maximum WDS/5 min., 4) total glutamate release events, 5) average 
peak size and 6) release periodicity (dependent variables).  We also calculated 
the linear regression lines for total glutamate release events verses total WDS 
and for average glutamate peak size verses average WDS/ 5 minutes to 
determine any correlations between behavior and spontaneous glutamate 
neurotransmission.  Linear regression analysis determined if r2 was significantly 
different than zero (statistical significance defined as p < 0.05) 
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In vivo Glutamate Studies in Unanesthetized Non-human Primates 
SG-2 Calibration Specifications 
 To characterize the SG-2 MEAs on the day of experimentation, in vitro 
calibrations were performed.  The same skin Ag/AgCl reference electrode used 
during calibration was later used during the animal experiments.  SG-2 MEAs 
responded linearly to serial aliquots of glutamate (r2 > 0.99), and demonstrated at 
least 95% AA blockade (glutamate:AA = 20:1).  The calibration parameters for 
the SG-2 used in these experiments were (n = 6, mean ± S.E.M.): glutamate 
sensitivity: 3.5 ± 0.4 pA/µM; limit of detection: 2.7 ± 0.8 µM.  
 
Surgical Procedures 
 Under sterile field conditions, a cannula was surgically implanted allowing 
chronic unilateral access to the ventral putamen (left hemisphere: NHP 1 and 2; 
right hemisphere: NHP 3).  The cannula was a modified winged I.V. catheter 
(16G, JELCO, Tampa, FL) fitted with a stainless steel cap (Figure 2.3).  The 
brain coordinates for implantation were determined by magnetic resonance 
imaging (MRI) before surgery, and confirmed post-implantation (NHP 1, AP (from 
ear bars): +20 mm, ML: +11 mm, DV (from dura): -12 mm; NHP 2, AP: +18 mm, 
ML: +10.5 mm, DV: -15 mm; NHP 3, AP: +21.5 mm, ML: -11 mm, DV: -14.5 mm, 
Figure 2.6).  The animals were anesthetized with isoflurane (1-3%) during these 
procedures and were allowed at least a 2 week recovery period before the first 
day of experimentation.    
 
Tonic Glutamate Measurements   
 Animals were previously trained and extensively handled by the 
experimenters.  Studies were performed in a non-human primate behavioral 
laboratory while the animals were seated in a MRI-compatible primate chair, 
which allowed free movement of the limbs and body but restrained the head 
(Figure 2.8) (Andersen et al., 2002).  The SG-2 was lowered into the putamen 
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through the indwelling cannula.  Similar to the basic science MEA technology 
developed in our laboratory for glutamate measurements in unanesthetized 
rodents (see In vivo Amperometric Recordings in Unanesthetized Rats), the SG-
2 MEAs were connected to a miniature 4-channel low noise potentiostat and the 
FAST-16 electrochemistry instrument via a locking AMS plug (Figures 2.3 and 
2.8).  For these studies we used a non-invasive skin Ag/AgCl reference electrode 
which was modified to plug directly into the miniature potentiostat (Figure 2.8).  
Two depths in the putamen (2 mm apart) were targeted with the SG-2.  The SG-2 
was lowered manually utilizing millimeter increments marked on the SG-2 shaft.  
Glutamate was measured continuously (2 Hz) for around 40 minutes at each 
depth.  Approximately four months after the first experiments, the studies were 
repeated to determine the reproducibility of the glutamate measurements.        
 
Data Analysis   
 GraphPad Prism 5 was used for all statistical analysis.   In vitro 
calibrations were performed to determine the effects of sterilization on SG-2 MEA 
function.  Based upon empirical data, an MEA sensitivity to glutamate of 1 pA/µM 
or greater is considered functional.  The percentage of SG-2 MEAs with at least 
one functional recording site was determined for each batch (1 and 11 month 
storage times).  The average glutamate sensitivity and LOD for the functional 
sites was calculated.  To determine if storage duration significantly affected MEA 
performance, a Student’s t-test was used to compare the sensitivity and LOD 
between the batches.    
 Following a thirty minute stabilization period at each depth targeted by the 
SG-2, tonic glutamate was measured.  Combining data from the first and the 
follow-up experiments, we compared the tonic glutamate levels in the dorsal 
putamen to levels in the ventral putamen with a Paired t-test (n = six each depth).  
We also compared the reproducibility of the basal glutamate levels between the 
first and follow-up recordings with a Paired t-test for repeated measures (n = 6).   
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Figure 2.1 S2 MEA Configuration for Self-referenced  
Glutamate Measurements 
 
S2 MEA image with illustrations showing Nafion exclusion layer, bovine serum 
albumin-glutaraldehyde inactive protein matrix (BSA-Glut) and glutamate-oxidase 
(GluOX) active enzyme coatings. S2 MEAs have four platinum recording sites 
(15 x 333 µm each).  A) Sites prepared for glutamate detection: current is 
generated when the hydrogen peroxide (H2O2) “reporter molecule” is oxidized (2 
electrons, +0.7 V vs. Ag/AgCl reference electrode).  B) Sentinel sites (without 
GluOX): subtraction of current measured with ‘B’ sites from current measured 
with ‘A ’sites serves to isolate current generated by enzymatic breakdown of 
glutamate.  This is termed self-referencing.  Note that Nafion prevents oxidation 
of ascorbic acid and DOPAC.  In lieu of Nafion, meta-phenylenediamine (mPD) 
can be electroplated to the recording sites which prevents oxidation of ascorbic 
acid, DOPAC and DA. 
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Figure 2.2 Various Electrodes with S2 MEA Configuration 
 
Top panel: Ceramic paddle electrode used for glutamate measurements in 
anesthetized rats with attached glass pipette for local drug application (Stephens 
et al., 2008); bottom panel: modified ceramic paddle electrode (‘rat pedestal’) for 
chronic glutamate measurements in unanesthetized rats with attached stainless 
steel guide cannula for local drug application (Hascup et al., 2006). 
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Figure 2.3 Spencer-Gerhardt-2 Microelectrode Array 
 
A) Cannula and stainless steel cap for chronic access to the NHP putamen.  B) 
SG-2 MEA, inset: side-by-side comparison of SPENCER Probe Depth Electrode 
and SG-2 ceramic tip.  C)  Magnification of SG-2 ceramic tip (same as the S2 
MEA), showing configuration of platinum recording surfaces for self-referenced 
glutamate measurements (Stephens et al., 2009b).   
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Figure 2.4 Calibration of S2 MEA  
 
Platinum recording sites are submerged in phosphate-buffered saline (0.05 M, 
pH 7.4, 37°C) and serial aliquots of glutamate (20 mM) added to yield final buffer 
glutamate (Glu) concentrations of 20, 40 and 60 µM.  Standard response curves 
(dashed line, r2 > 0.99) are generated and used to equate a change in current 
from the oxidation of hydrogen peroxide with a proportional change in glutamate 
concentration (Burmeister and Gerhardt, 2001).  The slope of the calibration 
curve is referred to as the microelectrode sensitivity to glutamate (pA/µM). 
Microelectrodes were also exposed to an ascorbic acid (AA, 250 µM) challenge 
to test effective blockade of electrochemical interferents, and to hydrogen 
peroxide (H2O2) as a positive control.  Current produced from the oxidation of 
dopamine (DA) or other interferents can be removed by self-referencing.   
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Figure 2.5 Microelectrode Placements in the Trisynaptic Pathway 
 
Left: Fast Green (Sigma-Aldrich) staining in the hippocampal formation 
confirming placement of the MEA/micropipette assembly in the CA1 and CA3 
subregions (upper panel) and the DG subregion (lower panel) during 
anesthetized rat studies.  Right:  MEA tracts in the hippocampal subregions 
targeted with chronic MEA implants confirming accurate placement in the DG, 
CA3 and CA1 during studies in unanesthetized rats.  Note:  During experiments 
in anesthetized rats, one MEA was used to measure glutamate in all the 
hippocampal subregions.  In contrast, chronic MEA implants used for glutamate 
recordings in unanesthetized rats cannot be moved, therefore only one subregion 
could be studied in each animal. 
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Figure 2.6  MRI Images of Chronic Cannula Placement in the NHP Putamen 
 
Images confirm placement of the guide cannula allowing unilateral access of the 
SG-2 to the putamen of non-human primates. 
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Figure 2.7 Measuring Basal Glutamate 
 
Subtraction of current measured with sentinel sites from current measured with 
glutamate oxidase (GluOX) coated sites serves to isolate current generated by 
enzymatic breakdown of glutamate.  This is termed self-referencing.  Dividing the 
self-referenced current (pA) by the MEA sensitivity to glutamate (slope of the 
calibration line (pA/µM)) = Resting glutamate (GluRest (µM)).   
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Figure 2.8 Experimental Set-up for Amperometric Studies in Awake-
behaving NHPs 
 
Illustrations provide a lateral view of the NHP chair and FAST-16 recording 
system, and an anterior view of the NHP during glutamate recordings. a) Ag/AgCl 
skin reference electrode, b) potentiostat (headstage), c) SG-2 MEA, d) NHP 
chair, e) ground wire, f) connector, g) FAST-16, h) laptop computer. (Courtesy 
Tom Dolan) 
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Chapter Three:  Age-related Changes in Glutamate Release and Clearance 
in the Trisynaptic Pathway of Anesthetized F344 Rats  
 
Introduction 
  
 An understanding of how morphological and electrophysiological changes 
in brain regions critical for learning and memory translate into deficits in the 
cognitive functions of the hippocampus in aging is needed (for reviews see 
Rosenzweig and Barnes, 2003; Chawla and Barnes, 2007). In addition to 
preserved cell counts (West, 1993; West et al., 1993; Peters et al., 1996; Rapp 
and Gallagher, 1996; Rasmussen et al., 1996; Merrill et al., 2000; Merrill et al., 
2001), most of the basic cellular characteristics of hippocampal principal cells do 
not change with advanced age including but not limited to resting membrane 
potential and amplitude and duration of Na+-mediated action potentials (for 
review see Rosenzweig and Barnes, 2003). Therefore, changes in hippocampal 
cognitive functions during aging do not appear to be attributable to changes in 
neuron number or basic cellular physiology.  It is believed that structural changes 
in synaptic connections during aging affect functional connectivity in the 
hippocampus (reviewed by Rosenzweig and Barnes, 2003; Chawla and Barnes, 
2007); however, age-associated alterations in neurotransmission and 
subsequent effects on function of the hippocampal circuitry are far less defined. 
In the hippocampus, the chief excitatory neurotransmitter is L-glutamate. 
The NMDA and AMPA ionotropic glutamate receptor subtypes are critical for 
long-term potentiation and hippocampal-dependent learning and memory (Riedel 
et al., 2003). A reduction in ionotropic receptors and their constituent subunits 
with age has been correlated with a decline in memory function (Magnusson, 
1998a,b; Adams et al., 2001; Tang et al., 2001; Clayton et al., 2002) which can be 
modulated with pharmacological agents that facilitate activation of the glutamate 
receptors (Müller et al., 1994; Wu et al., 2002; Rosenzweig and Barnes, 2003). 
Thus, age-related changes in presynaptic and glial regulation of glutamate 
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availability for participation in receptor-dependent processes may also be needed 
to help explain age-related changes in hippocampal neuron function during 
aging.  
 Regulation of glutamate release and clearance in the hippocampus has 
been extensively investigated using ex vivo methods like brain slices, tissue 
homogenates and synaptosomes (for review see Segovia et al., 2001).  Due to 
the limitations of these methods the literature has been filled with contradicting 
reports about increases, decreases or no changes in glutamate regulation with 
aging. The dentate gyrus (DG), cornu ammonis 3 (CA3) and cornu ammonis 1 
(CA1) hippocampal subregions are distinct on a cellular, molecular and functional 
basis, and are intricately connected via the trisynaptic circuit (for review Miller 
and O’Callaghan, 2005; Greene et al., 2008). Isolating the hippocampus from its 
extrinsic connections and disrupting the intrinsic connections could account for 
the inconsistency in previous aging studies. Only two prior microdialysis studies 
have reported on hippocampal glutamate regulation during aging using intact 
animals and the results are contradicting. Zhang et al. (1991) showed a decrease 
and Massieu and Tapia (1997) showed an increase in tonic extracellular 
glutamate levels in aged as compared to young rats.  Though microdialysis does 
allow for in vivo measurements of tonic glutamate, controversy exists regarding 
the neuronal origin of the signals and its slow temporal resolution limits the ability 
to investigate the rapid release and clearance dynamics associated with 
glutamate neurotransmission (Timmerman and Westerink, 1997; Segovia et al., 
2001). This is important because alterations in release and/or clearance may not 
manifest with changes in tonic resting glutamate levels due to biological 
compensation, and therefore must be studied directly. Furthermore, due to the 
size of microdialysis probes (mm), the previous studies are limited because they 
do not address discrete subregional variation within the hippocampus.   
We have recently demonstrated altered regulation of glutamate 
neurotransmission during aging in the striatum of rodents (Nickell et al., 2005, 
2007) and the cortex of nonhuman primates (Quintero et al., 2007) using 
enzyme-based microelectrode arrays coupled to amperometry for in vivo 
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glutamate recordings. In addition to a sub-second (2 Hz) temporal resolution that 
allows for rapid measurement of glutamate release and clearance in the 
extracellular space, our microelectrode technology measures from brain 
parenchyma with a spatial-resolution (µm) superior to that of microdialysis 
(Stephens et al., 2008) allowing accurate targeting of the DG, CA3 and CA1 
subregions. The experiments presented here investigated the capacity of 
glutamate release and uptake in subregions of the hippocampus (DG, CA1 and 
CA3) in young, late-middle aged and aged Fischer 344 (F344) rats.  First, we 
studied the effects of aging on tonic (resting) levels of glutamate using a self-
referencing enzyme-based microelectrode array recording technology (Day et al., 
2006).  Second, we used local application of a high potassium solution to evoke 
reproducible synaptic overflow of glutamate with a micropipette attached to the 
microelectrode arrays. This was carried out to simulate phasic bursts of 
glutamate release and determine the effects of aging on depolarization-induced 
release of glutamate. Finally, using the attached micropipette for evoked release 
we locally applied finite amounts of glutamate to study the effects of aging on 
glutamate clearance. The present studies are the first to provide insight into age-
related changes in functional glutamatergic neurotransmission in subregions of 
the rat hippocampus. 
 
Materials and Methods 
 
 Please refer to Chapter Two for a detailed description of animal care, 
electrode preparation, electrode calibration, amperometric recording technique 
and methodology for measuring and comparing tonic and phasic glutamate 
neurotransmission across hippocampal subregions and age-groups. 
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Results 
 
  In these studies we utilized a novel microelectrode array recording 
technology to investigate the in vivo regulation of glutamate neurotransmission in 
the trisynaptic circuit of young, late-middle aged and aged F344 rats  with spatial 
(µm) and temporal (2 Hz) resolutions unique to the scientific literature.  
Histological evaluation confirmed MEA placement in the dendritic trees of the 
hippocampal principal cells in the DG, CA3 and CA1 subregions.  The co-
localized granule cell dendrites and entorhinal cortex terminals were targeted in 
the infrapyramidal blade of the DG.  In the stratum lucidum of CA3, the MEA was 
placed among mossy fiber terminals and their target CA3 pyramidal cell 
dendrites.  In CA1, MEA placement was confirmed in the suprapyramidal stratum 
radiatum were CA1 pyramidal cell dendrites and Schaffer collateral terminals are 
co-localized. 
 Self-referenced tonic glutamate recordings in the DG, CA3 and CA1 
hippocampal subregions were in the 3 µM range and showed no significant 
differences across the trisynaptic circuit within each age group (Figure 3.1, Table 
3.1): young, DG: 3.4 ± 0.5 µM, CA3: 2.8 ± 0.6 µM, CA1: 2.5 ± 0.5 µM, F(2,35) = 
2.72, p = 0.08; late-middle aged, DG: 2.9 ± 1.1 µM, CA3: 3.3 ± 0.7 µM, CA1: 2.1 
± 0.5 µM, F(2,24) = 0.80, p = 0.46; aged DG: 2.9 ± 0.5 µM, CA3: 3.0 ± 0.4 µM, 
CA1: 2.8 ± 0.4 µM, F(2,41) = 0.046, p = 0.96.  Average tonic glutamate levels did 
not change for any individual subregion when compared across age groups (DG, 
F(2,34) = 0.19, p = 0.83; CA3, F(2,34) = 0.19, p = 0.83; CA1, F(2,34) = 0.65, p = 
0.53). Thus, the resting or tonic levels of glutamate seem little affected with aging 
in the hippocampus, at least under these conditions and in anesthetized animals. 
 Application of KCl (70 mM, isotonic, pH 7.4, 12.5-75 nL) allowed us to 
produce discrete and well-defined stimulation of the local environment around the 
microelectrode, resulting in robust (5-60 µM) and reproducible (every 60 
seconds) release of glutamate from terminals in the DG, CA3 and CA1 
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hippocampal subregions (Figure 3.2).  Results are summarized in Table 3.2.  The 
mean maximum amplitude of KCl-evoked glutamate signals was significantly 
increased in the DG of late-middle aged rats compared to young (p < 0.05) and 
aged (p <0.05) rats (DG: young, 19.6 ± 3.9 µM; late-middle aged, 36.2 ± 7.7 µM; 
aged, 17.3 ± 1.8 µM, F(2,16) = 4.3, p = 0.032).  The variances of these data were 
significantly different across age groups (Bartlett’s test, p = 0.038).  Though no 
significant difference existed in the maximum amplitude of glutamate signals 
recorded by the microelectrode in the young and aged DG, the first order rate of 
decay of the signals was significantly faster in the aged rats as compared to the 
young rats (0.29 ± 0.03 sec-1 vs. 0.21 ± 0.02 sec-1 respectively; t-test p = 0.036), 
indicating an increased clearance capacity of the aged DG following phasic 
release of glutamate (Figure 3.4).  This was further investigated with exogenous 
glutamate clearance studies. 
 Perhaps of greatest interest was that the CA3 subregion showed 
significantly less glutamate release following KCl stimulation in aged rats when 
compared to young (p < 0.05) and late-middle aged (p < 0.05) animals (young, 
14.6 ± 1.5 µM ; late-middle aged, 16.7 ± 2.6 µM; aged, 8.4 ± 2.4 µM,  F(2,13) = 
3.82, p = 0.0495).  Diminished release in CA3 also contributed to significantly 
altered glutamate release capacities throughout the trisynaptic circuit within the 
late-middle aged and aged groups.  Compared to the DG in each respective 
group, the CA3 and CA1 subregions had significantly less glutamate release 
following KCl stimulation (late-middle aged: DG, 36.2 ± 7.7 µM; CA3, 16.7 ± 2.6 
µM, p < 0.05; CA1, 16.5 ± 5.4 µM, p < 0.05; F(2,14) = 3.76, p = 0.0493; aged: 
DG, 17.3 ± 1.8 µM; CA3, 8.4 ± 2.4 µM, p < 0.05; CA1, 10.9 ± 2.3 µM, p < 0.05; 
F(2,13) = 4.89, p = 0.026).  In contrast to the DG and CA3, no age-associated 
changes in maximum amplitude of evoked-glutamate signals were seen within 
the CA1 subregion across age groups (young, 12.7 ± 2.7 µM; late-middle aged, 
16.5 ± 5.4 µM; aged, 10.9 ± 2.3 µM, F(2,15) = 0.47, p = 0.63).    Thus, the major 
findings of this study were increased glutamate release from the entorhinal cortex 
terminals in the DG of late-middle aged rats, decreased glutamate release from 
mossy fiber terminals in the CA3 of aged rats and diminished glutamate release 
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capacity during aging from the mossy fibers and Schaffer collaterals comprising 
the trisynaptic circuit downstream of the DG. 
 To better determine potential age-related changes in glutamate uptake we 
locally applied an exogenous glutamate solution (100 µM in 0.9% saline, pH 7.4) 
into the DG, CA3 and CA1 hippocampal subregions of all three age groups to 
study clearance of glutamate from the extracellular space by glia and neuronal 
elements.  Volumes ranging from 25-250 nL were delivered intracranially to 
obtain signals with maximum amplitudes in the range most frequently obtained 
during the KCl-evoked glutamate release studies (10-20 µM).  Because the high-
affinity glutamate transporters operate under Michaelis-Menton kinetics, it is 
important to compare clearance rates where experimental conditions supply 
approximately the same amount of substrate to transporters as physiological 
conditions.  Actual maximum amplitudes analyzed across subregions and age 
groups were not statistically different (data not shown, ANOVA, p = 0.17); 
therefore, variability in the size of peaks analyzed did not contribute to 
differences in uptake rate.   
 Results of the exogenous glutamate clearance experiments are 
summarized in Table 3.3.  In the DG of aged rats, the glutamate uptake rate was 
significantly faster compared to the uptake rate in the DG of young rats (5.5 ± 0.7 
µM/sec vs. 3.3 ± 0.4 µM/sec, p < 0.05), with the late-middle aged rats falling in 
between (4.1 ± 0.6 µM/sec; F(2,22) = 3.88, p = 0.036) (Figures 3.3 and 3.4).  
Also, within the aged trisynaptic circuit uptake rates were significantly different 
(F(2,19) = 5.38, p = 0.014), showing a faster clearance rate in the DG (5.5 ± 0.7 
µM/sec) when compared to the other hippocampal subregions (CA3: 3.7 ± 0.5, p 
< 0.05; CA1: 3.9 ± 0.4, p < 0.05) (Figure 3.4).  No significant differences in 
uptake rate across the trisynaptic circuit were seen in the young and late-middle 
aged groups: (young, DG: 3.3 ± 0.4 µM/sec, CA3: 4.2 ± 0.4 µM/sec, CA1: 4.0 ± 
0.3 µM/sec, F(2,24) = 1.68, p = 0.21; late-middle aged, DG: 4.1 ± 0.6 µM/sec, 
CA3: 4.4 ± 0.4 µM/sec, CA1: 4.5 ± 0.5 µM/sec, F(2,29) = 0.18, p = 0.84).  The 
uptake rate within the CA3 and CA1 subregions was not different across age 
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groups (F(2,22) = 0.86, p = 0.44 and F(2,29) = 0.61, p = 0.55, respectively) 
(Figure 3.3).      
 
Discussion 
 
 In this study, we have shown that tonic glutamate levels in the discrete 
DG, CA3 and CA1 subregions of the hippocampus do not change significantly 
during aging in anesthetized F344 rats.  However, the trisynaptic pathway did 
exhibit changes in glutamate release and uptake in specific subregions.  
Interestingly, evoked release of glutamate was greatest from perforant path 
terminals in the DG of late-middle aged rats as compared to young and aged 
animals.  The most fascinating finding was that the CA3 subregion exhibited 
profound dysregulation during aging.  Mossy fiber terminals in CA3 had 
diminished evoked glutamate release in aged rats compared to young and late-
middle aged animals.  Also, alterations within the trisynaptic circuit during aging 
showed a significant loss of glutamate release capacity in CA3 (mossy fibers) 
and CA1 (Schaffer collaterals) compared to the DG (perforant path) in both late-
middle aged and aged rats.  These findings suggest a diminished function or 
competence of the glutamate fibers in aging animals.  Finally, the aged DG 
showed a significantly increased glutamate uptake capacity compared to the DG 
of young animals, suggesting that the increased glutamate release in late-middle 
aged rats may result in increased glutamate uptake in aged rats.  
 
Aging Does Not Alter Tonic Glutamate Levels in the Trisynaptic Circuit 
 Only two in vivo studies of resting glutamate in the hippocampus during 
aging have been reported.  Their results are contradicting, showing an increase 
in aged compared to young Wistar rats (Massieu and Tapia, 1997) and a 
decrease in aged compared to young F344 rats (Zhang et al. 1991).  A 
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shortcoming of these studies is the lack of subregional resolution attained due to 
the large size of the microdialysis probes utilized.  
 In contrast to the previous in vivo studies, our data show that resting 
glutamate levels were approximately equal throughout the individual subregions 
of the trisynaptic circuit across age groups.  We caution that these results too 
could be misleading.  Our laboratory has recently begun to appreciate that 
urethane anesthesia can lower resting glutamate levels in the striatum and pre-
frontal cortex (Rutherford et al., 2007).  Tonic glutamate concentrations across 
the hippocampus could be affected by anesthesia.  However, the microelectrode 
technology used in these studies is the first in vivo technology that allows for 
measures of resting glutamate in discrete subregions of the trisynaptic circuit.  
Additional studies are needed in unanesthetized rats to determine the effects of 
aging on resting levels of glutamate.  
 
Aging Alters Stimulus-evoked Glutamate Release in the Trisynaptic Circuit 
 In these studies we showed that significantly less glutamate release was 
evoked by local KCl application in the CA3 subregion of aged rats compared to 
the CA3 of young and late-middle aged rats.  In the late-middle aged and aged 
groups, glutamate release was impaired from terminals in both CA3 and CA1 
when compared to terminals in the DG.  A decrease in stimulus-evoked 
glutamate release in the hippocampus with aging has been previously 
demonstrated in brain slices (Freeman and Gibson, 1987).  Diminished 
glutamate release indicates that less glutamate is available for receptor 
activation, potentially altering the relay of glutamatergic neurotransmission 
through the trisynaptic circuit which is critical for hippocampal-dependent learning 
and memory.  
 The CA3 subregion has been repeatedly identified as having age-
associated neurochemical alterations (Le Jeune et al., 1996; Kadar et al., 1998; 
Adams et al., 2001).  Mossy fiber projections to CA3 have shown age-associated 
changes in dynorphin, an opioid-like peptide believed to be intimately involved 
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with glutamatergic neurotransmission.  Zhang et al. (1991) showed that an 
increase in dynorphin was localized to the DG granule cells and their MF 
projections in F344 rats, which correlated with an impaired memory performance 
and decreased glutamate release in vivo; however, their microdialysis study 
lacked anatomical resolution, localizing the diminished glutamate response only 
to the ventral hippocampus.  Loss of glutamate release capacity in the CA3, both 
in aged compared to younger animals and within the trisynaptic circuitry of late-
middle aged and aged rats, is perhaps our most important finding.  These 
experiments have potentially exposed the functional outcomes of the age-
associated molecular changes in mossy fiber inputs previously described in the 
literature.   
 Our in vivo studies also showed that the DG subregion was significantly 
altered in late-middle aged rats as compared to younger and older animals 
because glutamatergic terminals in the late-middle aged DG released more 
neurotransmitter following local KCl stimulation.  The augmented evoked-release 
of glutamate from perforant path fibers in the DG indicates that changes in input 
to the hippocampal formation occur by late-middle age.  An age-related increase 
in glutamate release has also been reported in brain slices (Meldrum et al., 1992; 
Saransaari and Oja, 1995).  Prior work has shown that synapses from afferent 
projections to the DG decrease with age, but the remaining synapses are 
electrophysiologically stronger (reviewed by Geinisman et al., 1996).  Until now, 
the effects of these age-associated changes on glutamatergic neurotransmission 
in vivo have never been specifically investigated in the DG subregion.   
 A compensatory increase in synaptic strength is supported by our data 
because we showed an enhanced evoked glutamate release in late-middle aged 
rats.  From this we can conclude that more glutamate is available from perforant 
path terminals in the late-middle aged DG to participate in glutamate-dependent 
processes.  This is important because age-associated alterations in hippocampal 
connectivity due to loss of synapses may not immediately result in functional 
changes due to the ability of the late-middle aged glutamatergic afferents to the 
DG to compensate.  The return in the aged DG to evoked glutamate release 
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levels seen in young animals led us to two interesting, yet very different 
conclusions about the effects of aging on glutamate release in the DG.  First, 
assuming the augmented release of glutamate in late-middle aged animals is a 
compensatory response to synaptic loss, the inability of the aged DG to maintain 
the increase may explain the loss of cognitive function in these animals.  
Alternatively, the aged DG may not be exhibiting a loss of compensation, but 
rather a different mechanism of compensation.  The first order rate of glutamate 
clearance following evoked release was significantly faster in the aged DG 
compared to the young, even though the maximum release of glutamate 
measured by the microelectrode in both age groups was not significantly 
different.  We believe the aged DG develops a compensatory increase in 
clearance capacity in response to the increased glutamate release in late-middle 
age.   This is further supported by our exogenous glutamate clearance data.  
Increased clearance ability in the aged DG may be masking an increase in 
perforant path evoked-glutamate release similar to that seen in late-middle aged 
animals, such that higher release of glutamate in the aged DG is not measured 
by the electrode because a significant portion is rapidly cleared following release.  
If the increase in glutamate release during aging exceeds compensation and 
becomes pathologic, the faster glutamate clearance in aged animals may be a 
neuroprotective mechanism against excitotoxicity.        
 
Aging Alters Glutamate Clearance in the Trisynaptic Circuit 
 Our data indicate that the DG acquires significant glutamate clearance 
capacity with age, showing approximately a 66% increase in the uptake rate of 
aged rats as compared to young rats.  A significant increase is seen when the 
DG is compared to other trisynaptic subregions within the aged hippocampus as 
well.  These data are in contrast to prior work that has shown no consistent 
changes in glutamate clearance with aging (Najerahim et al, 1990; Gilad et al., 
1990; Palmer et al., 1994).  Glutamate clearance from the synaptic cleft is 
controlled by uptake and diffusion (Sykova, 2005).   Approximately ninety percent 
 57 
 
of glutamate uptake is performed by high affinity transporters (GLAST, GLT-1) 
located predominantly on astroglia (for review see Danbolt, 2001).  Sykova et al. 
(2002) showed that a decrease in extracellular space (ECS) and loss of glial 
organization, especially in the DG, were evident in aged rats that were impaired 
learners.  The aged F344 hippocampus maintains numbers of GFAP+ astrocytes 
at young levels (Hattingly and Shetty, 2008), so it is possible that age-associated 
gliosis may be due to an increase in the fibrous character of astrocytes rather 
than an increase in astrocyte number (Wu et al., 2005).  Sykova et al. (2002) 
proposed that the compacted ECS could predispose the aging population to 
excitotoxicity due to synaptic ‘trapping’ of glutamate.   
 We believe the increased clearance capacity of the aged DG could be a 
very effective neuroprotective mechanism against over-activation of glutamate 
receptors resulting from age-associated increases in release capacity of 
glutamate terminals in the DG and excitotoxic trapping due to gliosis.  The 
significant increase in uptake rate is likely related to increased surface 
expression of transporters on glia and neurons. We have recently reported that 
decreased surface expression of GLAST may contribute to slower regulation of 
glutamate uptake in the dorsal rat striatum (Nickell et al., 2007).  How aging 
affects the function of astrocytic glutamate transporters in the hippocampus is a 
critical piece of information not yet fully understood.  Additional studies are 
needed to investigate the mechanism(s) involved with enhanced clearance of 
glutamate in the aged DG observed in the present study. 
 To our knowledge, this is the first study describing age-associated 
subregional heterogeneity of hippocampal glutamatergic neurotransmission in 
vivo.  Though tonic levels of glutamate in the extracellular space were 
unchanged with aging, we were able to show subregion-specific alterations in 
stimulus-evoked glutamate release and clearance capacity in the trisynaptic 
circuit during aging.  Taken with our previous aging studies in the rodent striatum 
and non-human primate cortex, we can begin to outline the vast variability of 
CNS susceptibility to changes in glutamate regulation during aging.  
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Figure 3.1 Mean Tonic Glutamate Concentrations in the                 
Trisynaptic Circuit During Aging 
 
Aging did not significantly alter tonic glutamate levels in the DG (F(2,34) = 0.19,            
p = 0.83), CA3 (F(2,34) = 0.19, p =0.83) or CA1 (F(2,34) = 0.65, p = 0.53). 
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Figure 3.2 Representative Glutamate Release Signals Following Local 
Application of KCl in the Trisynaptic Circuit of F344 Rats During Aging 
 
Each symbol in the traces is an individual glutamate measurement (2 Hz).  Inset 
signals show reproducibility of evoked-glutamate release signals.  Right: Bar 
graphs represent the mean maximum amplitude of glutamate signals across the 
trisynaptic circuit.  Terminals in CA3 and CA1 had significantly less glutamate 
release compared to terminals in the DG in the 18 mo. and 24 mo. groups.  
Bottom: Graphs represent the mean max. amplitude of glutamate signals across 
age groups.  Each symbol is an individual animal.  The perforant path terminals 
in the DG of late-middle aged rats released more glutamate compared to young 
and aged rats.  The mossy fiber terminals in the CA3 of aged rats released less 
glutamate compared to young  and late-middle aged animals.   
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Figure 3.3 Mean Glutamate Uptake Rate Following Local Application of 
Exogenous Glutamate in the Trisynaptic Circuit of F344 Rats During Aging 
 
Following local application of exogenous glutamate (100 µM), uptake rate was 
significantly faster in the aged DG compared to young rats.  Within the aged 
trisynaptic circuit, uptake rates were significantly different showing faster 
glutamate uptake rate in the DG when compared to CA3 and CA1. 
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Figure 3.4 Comparison of Amplitude-matched Signals in the DG Showing 
Faster Clearance of Glutamate in Aged Animals 
 
Each symbol is an individual glutamate measurement (2 Hz).  Arrow indicates 
local application of exogenous glutamate (100 µM in 0.9% saline, pH 7.4).  Inset: 
KCl-evoked glutamate signals in DG of young and aged rats.  Aged rats have a 
faster first order rate of glutamate clearance.  Dashed line indicates predicted 
maximum amplitude of glutamate signal in an aged animal without increased 
glutamate clearance capacity.  
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Table 3.1 Tonic Glutamate in the Hippocampus of Anesthetized Rats [µM] 
 
Age 
 
DG 
 
CA3 
 
CA1 
 
Comparison Across   
Tri-synaptic Circuit 
(One-way ANOVA) 
Young a 3.4 ± 0.5 2.8 ± 0.6 2.5 ± 0.5 p = 0.08 
Late-middle aged b 2.9 ± 1.1 3.3 ± 0.7 2.1 ± 0.5 p = 0.46 
Aged c 2.9 ± 0.5 3.0 ± 0.4 2.8 ± 0.4 p = 0.96 
 
Comparison Across 
Age Groups Within 
Each Subregion 
(One-way ANOVA) 
 
 
 
 
p = 0.83 
 
 
 
p = 0.83 
 
 
 
p = 0.53 
 
                                                                              Values expressed as Mean  ± SEM 
a
 3-6 months; DG n = 15, CA3 n = 12; CA1 n = 13 
b
 18 months; DG n = 6, CA3 n = 11; CA1 n = 10 
c
 24 months; DG n = 16, CA3 n = 14; CA1 n = 14 
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Table 3.2  Potassium-evoked Glutamate Release in the  
Tri-Synaptic Circuit During Aging [µM] 
 
Age 
 
DG 
 
CA3 
 
CA1 
 
Comparison Across  
Tri-synaptic Circuit 
(One-way ANOVA) 
Young a 19.6 ± 3.9 14.6 ± 1.5 12.7 ± 2.7 p = 0.06 
Late-middle aged b ‡,α 36.2 ± 7.7 #16.7 ± 2.6 ◊16.5 ± 5.4 
 
 
 
 
*p = 0.049 
 #CA3 < DG, p < 0.05  
◊CA1 < DG, p< 0.05 
Aged c 17.3 ± 1.8 ¥, €,†8.4 ± 2.4 Ω10.9 ± 2.3 
 
 
*p = 0.026 
†CA3 < DG, p < 0.05 
ΩCA1 < DG, p < 0.05 
 
Comparison 
Across Age 
Groups Within 
Each Subregion 
(One-way 
ANOVA) 
 
 
 
 
*p = 0.032 
‡ Late-middle 
aged  > Aged,  
p < 0.05 
αLate-middle 
aged > Young,  
p < 0.05 
 
 
 
 
*p = 0.049 
¥ Aged < Late-
middle aged,  
p < 0.05 
€Aged < Young,  
p < 0.05 
 
 
 
 
p = 0.86 
 
All values represent mean  ± S.E.M. of glutamate release following local application of 50 nL KCl (70mM, isotonic, pH 7.4) 
a
 3-6 months; DG n = 8, CA3 n =6; CA1 n = 6 
b
 18 months; DG n = 5, CA3 n = 5; CA1 n = 7 
c
 24 months; DG n = 6, CA3 n = 5; CA1 n = 5 
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Table 3.3  Clearance of Glutamate in the Tri-Synaptic Circuit during Aging 
µM/sec 
 
Age 
 
DG 
 
CA3 
 
CA1 
 
Comparison Across 
Tri-synaptic Circuit 
(One-way ANOVA) 
Young a 3.3 ± 0.4 4.2 ± 0.4 4.0 ± 0.3 p = 0.21 
Late-middle aged b 4.1 ± 0.6 4.4 ± 0.4 4.5 ± 0.5 p = 0.84 
Aged c †,#,◊5.5 ± 0.7 3.7 ± 0.5 3.9 ± 0.4 
*p = 0.014 
#DG > CA3, p < 0.05 
◊DG > CA1, p < 0.05 
 
Comparison 
Across Age 
Groups Within 
Each Subregion 
(One-way ANOVA) 
 
 
 
 
*p = 0.036 
†Aged > 
Young, 
p < 0.05 
 
 
 
p = 0.61 
 
 
 
p = 0.55 
 
All values represent mean  ± S.E.M. of uptake rate following local application of exogenous glutamate (100µM, pH 7.4) 
a
 3-6 months; DG n = 9, CA3 n = 7; CA1 n = 11 
b
 18 months; DG n = 7, CA3 n = 12; CA1 n = 13 
c
 24 months; DG n = 8, CA3 n = 6; CA1 n = 8 
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Chapter Four: Age-associated Changes in Hippocampal Glutamate 
Regulation Significantly Correlate With Status Epilepticus Behavior and 
Spontaneous Glutamatergic Neurotransmission  
 
Introduction 
 
 The elderly population is the fastest growing age group in the United 
States (Collins et al., 1997).  Studies have established that the elderly population 
has an increased risk for status epilepticus (SE) and status-related morbidity and 
mortality (DeLorenzo et. al., 1992).  During aging, numerous alterations occur in 
the brain, including anatomical and physiological changes in the hippocampus 
(see Chapter Three) which is the most common brain structure involved in 
seizure disorders (Leppik et al., 2006).  It can be hypothesized that aging of the 
CNS may directly affect seizure susceptibility.  Age-associated alterations in the 
hippocampus that might predispose older individuals for SE need to be identified 
and studied.  In addition, an understanding of how aging contributes to the 
increased severity of SE observed in elderly patients is also needed.   
 It has been widely suggested that dysregulation of excitatory 
neurotransmission involving glutamate is a predominant mechanism of age-
associated increases in hippocampal vulnerability to neurodegenerative disease 
(for review see Danbolt, 2001; Segovia et. al., 2001).   Availability of 
neurotransmitter for participation in glutamate receptor-dependent processes 
(normal and excitotoxic) is a dynamic balance of release and uptake (Segovia et 
al., 2001).  One approach for investigating glutamate regulation involves looking 
for changes in tonic glutamate levels as an indication of disruption in glutamate 
release and/or uptake.  To investigate in vivo neurotransmission, microdialysis 
coupled with high-performance liquid chromatography has traditionally been the 
gold standard though this technique has some significant limitations including 
slow sampling rates (minutes), poor spatial resolution (mm) and significant CNS 
glial activation and cellular inflammation around the sampling area (Clapp-Lilly et. 
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al., 1999).  Only two studies using microdialysis have reported on age-associated 
changes in hippocampal tonic glutamate, and the results were contradictory 
(glutamate increased in aged animals, Massieu and Tapia, 1997; decreased in 
aged animals, Zhang et al., 1991).  Our laboratory uses enzyme-based ceramic 
microelectrode arrays (MEA) coupled to real-time amperometry to study in vivo 
glutamate neurotransmission without the limitations of microdialysis.  We can 
reliably measure tonic glutamate, as well as dynamic glutamate release and 
clearance events, in the mammalian CNS with sub-second temporal resolution 
(Burmeister et al. 2001, 2002; Pomerleau et al., 2003; Nickell et. al. 2005, 2007; 
Day et al., 2006; Quintero et al., 2007).  The small size of the MEA recording 
sites (µm) allows targeting of discrete hippocampal trisynaptic subregions (e.g. 
dentate gyrus (DG), cornu ammonis 3 (CA3) and cornu ammonis 1 (CA1), 
Stephens et al., 2009a).  Also, the MEAs have been shown to cause minimal 
disruption of the biological microenvironment evidenced by nominal glial 
activation, even after chronic implantation (Rutherford et al., 2007).    
 We recently showed that evoked-glutamate release and glutamate 
clearance capacity was significantly altered in the trisynaptic circuit of aged F344 
rats, but no changes were evident in tonic extracellular glutamate (Chapter 
Three).  Our tonic glutamate measurements were most likely affected by the 
presence of urethane anesthesia (Rutherford et al., 2007) warranting the current 
studies of tonic glutamate in awake-behaving animals, free of anesthetic effects.  
A clear benefit of conducting experiments in unanesthetized animals is the ability 
to incorporate behavioral experimental paradigms.  For the studies presented 
here, we were able to measure tonic glutamate levels in the hippocampus of 
young and aging animals and then examine the manifestation of SE as it related 
to age and pre-SE glutamate levels.          
 Convulsive SE animal models using 4-aminopyridine (4-AP) administration 
(systemic and intrahippocampal) have been an important experimental method 
for understanding the causal role of excitatory synaptic neurotransmission in 
seizure-related neuronal death (Pena and Tapia, 1999; Pena and Tapia, 2000; 
Ayala and Tapia, 2005).  Intrahippocampal 4-AP exposure results in robust EEG 
 68 
 
activity in rodents (Fragoso-Veloz et al., 1990; Medina-Ceja et al., 2000; Pena 
and Tapia, 1999; Pena and Tapia, 2000; Ayala and Tapia, 2005) which is 
accompanied by increased hippocampal extracellular glutamate (Pena and 
Tapia, 1999; Pena and Tapia, 2000; Morales-Villagran et al., 2008).  The need to 
monitor dynamic glutamate neurotransmission during SE has been recognized 
(Morales-Villagran et al., 2008) but never achieved on the second-by-second 
time scale of rapid glutamate release and clearance events (Danbolt, 2001).  The 
data presented here highlight the use of real-time amperometric measurements 
of glutamate as a novel assessment of glutamate regulation before, during and 
after seizure in a rodent model of human aging. 
 To our knowledge, no previous studies have reported on the use of the 4-
AP in aged animals, but we believe it is an attractive model because it can be 
applied intrahippocampally to cause limbic seizures and induces fast onset of SE 
with a single injection (Fragoso-Veloz et al., 1990).  Further supporting the utility 
of the 4-AP SE model, especially in aged animals, we determined through the 
course of this study that our experimental paradigm had zero mortality and 
produced self-terminating SE which allowed us to compare the SE duration as a 
function of age In summary, these studies were designed to investigate 
glutamate regulation in the hippocampus during normal aging, and to elucidate 
the potential relationship between glutamate dysregulation and rigor of SE in 
aging populations.  First, we studied the effects of aging on tonic glutamate levels 
in the DG, CA3 and CA1 subregions of the trisynaptic circuit of unanaesthetized 
animals using a self-referencing enzyme-based recording technology (Day et al., 
2006).  Second, we measured dynamic alterations in extracellular glutamate 
occurring in real-time during SE.  We accomplished this by coupling behavioral 
characterizations with amperometric recording techniques to monitor in vivo 
extracellular glutamate on a second-by-second basis.  We then compared SE-
associated behavioral events and dynamic glutamatergic neurotransmission 
across age groups.  Finally, we looked for lasting changes in glutamate 
regulation after SE by comparing pre- and post-SE tonic glutamate 
measurements.   
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Materials and Methods 
 
 Please refer to Chapter Two for a detailed description of animal care, 
electrode preparation, electrode calibration, amperometric recording technique, 
the 4-AP status epilepticus model and methodology for measuring and 
comparing tonic and phasic glutamate neurotransmission across hippocampal 
subregions and age-groups before, during and after SE. 
 
Results 
 
 Measurements obtained in unanesthetized F344 rats showed that tonic 
glutamate in the collective hippocampal formation in both late-middle aged (16.3 
± 3.0 µM) and aged rats (16.7 ± 3.2 µM) was significantly higher than young rats 
(8.4 ± 1.1 µM), F(2,52) = 3.479, p < 0.05 (Table 4.1).  The D’Agostino and 
Pearson omnibus normality test confirmed that the data were normally distributed 
(young: p = 0.232; late-middle aged: p = 0.414; aged: p = 0.190).  In all 
trisynaptic subregions there were late-middle aged and aged rats with tonic 
glutamate levels higher than young rats (mean ± S.E.M.): DG: young 7.9 ± 1.4 
µM, late-middle aged 17.5 ± 5.6 µM, aged 17.3 ± 12.6 µM; CA3: young 11.7 ± 
2.9 µM, late-middle aged 23.6 ± 5.3 µM, aged 22.2 ± 7.1 µM; CA1: young 6.2 ± 
1.0 µM, late-middle aged 9.1 ± 3.1 µM, aged 10.7 ± 4.3 µM, but comparisons of 
the individual subregions across age groups did not produce a particular 
subregion that was primarily responsible for the age-associated increase in 
hippocampal glutamate (DG F(2,18) = 1.990, p > 0.05; CA3 F(2,13) = 1.240, p > 
0.05: CA1 F(2,15) = 0.5208, p > 0.05) (Figure 4.1).     
 Self-referenced recordings showed spontaneous glutamatergic release 
events in CA1 after local application of 4-AP which persisted throughout SE, and 
was not due to movement artifact from SE-associated convulsions (i.e. wet-dog 
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shakes (WDS)) (Figure 4.2).  Spontaneous glutamate neurotransmission, 
characterized by a ‘peak’ in current recorded by the MEA as rapid release and 
clearance of glutamate in CA1 caused an increase in extracellular concentration 
followed by a quick return to baseline, was TTX (100 µM, 1 µL applied locally) 
sensitive (Figure 4.3).  Except for one young rat, the low dose 4-AP produced 
WDS behavior and spontaneous glutamate release events in all animals (Figure 
4.4).   All animals displayed WDS behavior and glutamate release events 
following the high dose (Figure 4.5).  A highly significantly dose effect was 
observed as all age groups showed increases in duration of SE (F(1, 14) = 71.70, 
p < 0.001), average WDS/ 5 minutes (F(1, 14) = 31.89, p < 0.001) and maximum 
WDS/ 5 minutes (F(1, 14) = 29.54, p < 0.001) after the high dose of 4-AP 
compared to after the low-dose.  All age groups also showed a significant 
increase in total glutamate release events during SE from high dose 4-AP (F(1, 
14) = 102.33. p < 0.001) compared to SE from low dose 4-AP.  The latency to 
onset of spontaneous glutamate release events (F(1, 14) = 0.49, p > 0.05), 
average peak size (F(1, 14) = 1.8, p > 0.05) and release periodicity (F(1, 14) = 
1.37, p > 0.05) did not change as a function of 4-AP dose.  More severe behavior 
(clonic spasms, rearing) was not seen in any of the animals, though use of 4-AP 
has been reported to cause these behaviors (Medina-Ceja et al. 2000).  Results 
are summarized in Tables 4.2 and 4.3.    
 Regression analyses showed that the status duration (r2 = 0.3667, F(1,15) 
= 8.685, p = 0.01), average WDS/ 5 minutes (r2 = 0.6136, F(1,15) = 23.82, p < 
0.001), maximum WDS/ 5 minutes (r2 = 0.6059, F(1,15) = 23.06, p < 0.001), and 
average glutamate peak size (r2 = 0.2375, F(1,15) = 4.67, p < 0.05) increased 
linearly with respect to pre-SE tonic glutamate levels obtained before 
experimentation with low dose 4-AP (Figure 4.6).  The total number of glutamate 
release events (r2 = 0.1819, F(1,15) = 3.33, p > 0.05) and the release periodicity 
(r2 = 0.006, F(1,15) = 0.081, p > 0.05) during SE did not significantly change due 
to pre-SE tonic glutamate concentration.  The behavioral and glutamate release 
characteristics of SE induced by high dose 4-AP did not correlate with pre-SE 
tonic glutamate: status duration (r2 = 0.0576,  F(1,15) = 3.33, p > 0.05), average 
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WDS/ 5 minutes (r2 = 0.0673, F(1,15) = 1.082, p > 0.05), maximum WDS/ 5 
minutes (r2 = 0.0472, F(1,15) = 0.7428, p > 0.05), total glutamate release events 
(r2 = 0.0344, F(1,15) = 0.5346, p > 0.05), average glutamate peak size (r2 = 
0.0515, F(1,15) = 0.8140, p > 0.05), release periodicity (r2 = 0.040,  F(1,15) = 
0.6315, p > 0.05).   
 Though pre-SE tonic glutamate did not correlate with behavior and 
spontaneous glutamate release during the more severe SE induced by high dose 
4-AP, age did significantly affect the high dose SE duration (F(2,14) = 5.96, p < 
0.05) and total glutamate release events (F(2,14) = 5.74, p < 0.05).  Aged rats 
experienced a longer duration of SE (105 ± 15 min.) than young rats (55 ± 10 
min., p < 0.01) and late-middle aged rats (66 ± 9 min., p < 0.05).  Related to the 
SE duration, total glutamate release events were also higher in aged rats (105.0 
± 14.8) than young rats (55.0 ± 10.3, p < 0.05) (Figure 4.5).  Average WDS/ 5 
minutes (F(2,14) = 0.92, p > 0.05), maximum WDS/ 5 min. (F(2,14) = 1.02, p > 
0.05), latency to onset of spontaneous glutamate release (F(1, 14) = 0.44, p > 
0.05), average peak size (F(2,14) = 0.48, p > 0.05) and release periodicity 
(F(2,14) = 2.46, p > 0.05) after high dose 4-AP were not affected by age.  Age 
did not significantly affect any of the behavioral or spontaneous glutamate 
release characteristics during SE induced by low dose 4-AP (p > 0.05 for all 
parameters) (Figure 4.4).  Results are summarized in Tables 4.2 and 4.3. 
 WDS behavior and glutamate release events were significantly correlated 
after both the low and high doses of 4-AP (Figure 4.7).  The quantity of WDS was 
linear with respect to the quantity of glutamate release events (low dose, r2 = 
0.7391; high dose, r2 = 0.5034).  During the low dose 4-AP experimental 
paradigm, the average number of WDS/ 5 minutes increased as the average size 
of the glutamate peaks increased (r2 = 0.3668).  This relationship was not seen in 
the high dose experimental paradigm.   
 Comparing tonic glutamate concentrations obtained before and after SE 
showed that exposure to 4-AP and the subsequent induction of SE did not 
significantly change tonic glutamate  in any age group (F(1, 14) = 0.50, p > 0.05).  
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Pre-SE vs. post-SE: young, 6.2 ± 1.0 µM vs. 7.8 ± 1.5 µM; late-middle aged, 9.1  
± 3.1 µM vs. 7.7 ± 2.7 µM; aged, 7.6 ± 3.8 µM vs. 9.1± 5.9 µM (Figure 4.8). 
 
Discussion 
 
 The studies in Chapter Three demonstrated age-associated alterations in 
glutamate release and clearance in the DG and CA3 hippocampal subregions of 
F344 rats.  One goal of the current study was to determine if previously 
demonstrated alterations in glutamate and release and clearance manifested 
with an age-associated change in tonic glutamate levels.  It was important to 
perform these experiments in unanesthetized animals to avoid influence of 
urethane anesthesia on tonic glutamate which confounded prior measurements.   
 A second goal of this study was to determine the influence of age on the 
expression of SE.   The quantification and characterization of rapid, 
spontaneous and highly synchronized glutamatergic release events that co-
manifested with the appearance of SE behavior provided a novel means to 
connect glutamate dysregulation and seizure pathology.  Tonic glutamate was 
shown to be significantly elevated in the hippocampal formation of late-middle 
aged and aged rats compared to young rats.  Pre-SE tonic glutamate significantly 
correlated with the rigor of SE after the low dose of 4-AP, as animals with the 
highest tonic levels experienced the most persistent and severe WDS behavior 
along with the largest glutamate peaks.  Regardless of pre-SE tonic glutamate 
levels, after the high dose of 4-AP significantly longer SE duration and more 
spontaneous glutamate release events were observed in aged animals.  Taken 
together these results indicate that a strong relationship exists between aberrant 
glutamate neurotransmission and SE, and also support an etiological role for 
age-associated glutamate dysregulation in epilepsy and SE which occur with 
disproportionately high frequency and severity in elderly populations.   
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Basal Glutamate Is Significantly Elevated in the Hippocampal Formation 
During Aging 
 Though no particular subregion showed a statistically significant increase 
in tonic glutamate during aging, when data from all subregions were combined 
within each age group, a significant elevation in tonic glutamate was seen in the 
collective hippocampal formation of late-middle aged and aged animals 
compared to young animals.  Mean tonic glutamate levels were approximately 
the same in the late-middle aged and aged groups indicating that onset of 
glutamate dysregulation occurs earlier than late-middle age, and persists 
throughout the remainder of the life span.  Animals with age-associated 
increases in DG and CA3 tonic glutamate seemed to contribute most to the 
significantly elevated levels in the collective hippocampal formation.  This is 
interesting because our prior work has shown that age-associated alterations in 
evoked- glutamate release and clearance are specific to the DG and CA3 
subregions, with no significant alterations occurring in CA1 (see Chapter Three). 
 The question remains, are age-associated changes in glutamate 
regulation cause, effect or compensation?  The answer probably depends on the 
animal.  Significant increases in evoked-glutamate release in the DG of late-
middle animals could be an initial substrate for increasing tonic glutamate levels 
during aging which cues the DG of aged animals to increase clearance capacity.  
A diminished CA3 evoked glutamate release in aged animals could certainly be 
interpreted as a mechanism contributing to loss of NMDAR-dependent learning 
and memory functions, but alternatively might be a compensatory response to 
elevated basal glutamate in the aging CA3, possibly mediated by mGluR auto-
regulation of presynaptic glutamate release.  It is important to note that even 
though some older animals did have elevated tonic glutamate, several animals in 
the late-middle aged and aged groups had tonic glutamate levels similar to young 
animals.  This could be interpreted to mean that effective compensatory 
mechanisms are in place in these ‘successfully’ aging animals, or that 
dysregulation never began in the first place.  A very interesting alternative 
interpretation is that these animals are not successfully aging.  According to 
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Geinisman and colleagues (1995), approximately two-thirds of aged animals are 
impaired on learning and memory tasks, and so it must be considered that the 
one-third of the our aging experimental populations with elevated tonic glutamate 
levels may function comparably to young animals in a scenario where increased 
extracellular glutamate compensates for synaptic loss, yielding aged animals that 
have maintained hippocampal function.  Definitive conclusions about the origin of 
increased tonic glutamate in the hippocampal formation, specifically in DG and 
CA3, cannot be made at this point, but it is important to reflect upon the fact that 
CA1 appears to be robust in the face of age-associated glutamate dysregulation, 
evidenced by prior studies and the tonic glutamate measurements presented 
here.  In the future, combining studies of glutamate regulation with memory 
testing could help discriminate the role of glutamate neurotransmission in 
maintenance of hippocampal function and successful aging of the trisynaptic 
circuit. 
 
Intrahippocampal 4-AP Causes Dose-dependent Status Epilepticus 
Characterized by Glutamate Bursting Activity and Limbic Behavior  
 Local application of 4-AP produced repetitive glutamate release events 
(~2 µM) that displayed a very rhythmic periodicity (approximately 1 peak per 
minute).  On average, spontaneous release activity began about 2 minutes after 
the administration of 4-AP.  Glutamate release events occurred throughout the 
duration of WDS behavior.  Regression analysis confirmed a significant 
correlation between total numbers of WDS and total glutamate release events 
during SE induced after both low and high doses of 4-AP.  The average peak 
size, release periodicity and latency to onset were not dose-dependent, but were 
sensitive to TTX which immediately halted spontaneous glutamate release and 
WDS behavior.  The total number of glutamate release events occurring during 
SE was dose dependent, as was the SE duration.  Together these data indicate 
that SE coincides with homogeneous, periodic neuronal glutamate release 
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events that persist for a given duration of time, dependent upon the severity of 
the seizure (i.e. low verses high dose 4-AP-induce SE).  
 All of the SE behavioral parameters (duration, average WDS/ 5 minutes, 
maximum WDS/ 5 minutes) were highly dose dependent.  This is especially 
interesting in light of the very consistent spontaneous glutamate release activity 
regardless of dose.  It is important to emphasize that the MEA measures 
glutamate through direct contact to the analyte, and is therefore measuring 
neurotransmission in a discrete area.  One interpretation of dose-dependent 
increases in behavioral severity and dose-independent spontaneous glutamate 
release, is that high dose 4-AP facilitated the recruitment of brain areas distal to 
the seizure focus (injection site).  Through the subsequent spread of 
synchronized neuronal firing, behavior became more severe while the 
spontaneous glutamatergic neurotransmission at the MEA remained constant in 
size and periodicity.  
 We now know that spontaneous glutamate release events initiate within 
five minutes after intrahippocampal (CA1) 4-AP injection, but this study was not 
designed to determine the latency of behavioral onset as behavior was tallied 
over five minute epochs and not on a second-by-second basis like the glutamate 
measurements.  A few animals did not display WDS until after the first five 
minute epoch, so we can conclude that spontaneous glutamate release activity 
preceded WDS behavior in these animals, although other seizure behaviors like 
oral automatisms may have had a shorter latency, but were more difficult to 
monitor and therefore not quantified.  Future studies should be designed to 
determine which comes first, bursting or behavior.  If it is determined that 
aberrant glutamate neurotransmission does in fact begin before behavior, 
spontaneous release could become a powerful biomarker of imminent seizure 
useful to therapeutic interventions aimed at halting synchronized neuronal firing 
before recruitment of adjacent brain areas and transition to overt seizure occurs. 
 These studies established that a key feature of the SE-associated 
glutamate release events was the uniformity of the peak size and periodicity after 
both low and high doses of 4-AP.  Average glutamate release events were 
 76 
 
approximately 2 µM in all age groups, but some animals had 3 - 4 µM peaks 
while others had 0.5 µM peaks.  This small variation about the mean had 
significant effects on the manifestation of WDS behavior after low-dose 4-AP.  
Regression analysis confirmed that animals with larger glutamate peaks 
averaged more WDS per 5 minute epoch.  Smaller glutamate bursts resulted in 
less WDS per 5 minute epoch.  These data fundamentally implicate 
dysregulation of dynamic glutamate neurotransmission in the progression of SE.     
 
Severity of Status Epilepticus is Predicted by Pre-Status Basal Glutamate 
 Perhaps the most important finding in this study for aging research is the 
significant correlation between pre-SE tonic glutamate levels in CA1 and the 
severity of SE following low-dose 4-AP.  Though tonic glutamate was not 
significantly increased in CA1 with age, some late-middle aged and aged rats 
had elevated levels compared to the rest of the animals in the study.  Animals 
with increased tonic glutamate experienced a longer SE duration, increased 
average and maximum WDS per 5 minute epoch and also larger spontaneous 
glutamate peaks.  Increased tonic levels indicate an underlying dysregulation in 
glutamate neurotransmission, though the mechanism cannot be identified with 
these studies.  Prophylactic steps to regulate tonic glutamate in high risk 
populations like the elderly could dramatically reduce SE related morbidity and 
mortality.       
 
Age Affects Status Epilepticus Behavior and Glutamate Bursting After High 
Dose 4-AP   
 Duration of SE behavior and the corresponding number of glutamate 
release events was significantly increased after high-dose 4-AP in the aged rats 
compared to younger animals.  This is intriguing because during severe SE, pre-
SE tonic glutamate no longer mattered, but rather age controlled the 
manifestation of WDS behavior and spontaneous glutamate release events.  This 
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indicates that properties of the aged hippocampus other than CA1 tonic 
glutamate levels predispose this population for severe seizures.  As mentioned 
earlier, we believe high-dose 4-AP may potentiate the spread of synchronous 
neuronal firing.  Recruitment of the other hippocampal subregions with known 
age-associated glutamate dysregulation, in addition to extrahippocampal brain 
areas that display altered glutamate regulation during aging (i.e. the striatum 
(Nickell et al., 2005, 2007), which is susceptible to 4-AP-induced status 
epilepticus, (Morales-Villagran and Tapis, 1996) may contribute to the increase in 
WDS behavior and spontaneous glutamatergic neurotransmission during severe 
SE in aged animals.    
 
Do 4-AP Mechanisms of Action Tell Us Anything About Aged 
Hippocampus? 
 At least acutely, the aged hippocampus appeared to recover from SE 
similarly to the young hippocampus, evidenced by consistent pre- and post-SE 
tonic glutamate levels.  It has been shown that 4-AP induced neurodegeneration 
can take up to five days, so chronic studies of post-SE tonic glutamate are 
needed to assess differences in glutamate neurotransmission as a result of 
neurotoxicity in each age group (Pena and Tapia, 1999).  
 The choice of 4-AP for our SE model was based upon the hypothesis that 
age-associated alterations in glial function could be exploited by 4-AP.  Consider 
the scenario where aged astrocytes have impaired transporter function.  This has 
been previously shown in the aged striatum (Nickell et al., 2006).  Because 
recovery of glutamate form the extracellular space occurs with reverse transport 
of a K+ ion, diminished glutamate recovery could result in increased intraglial K+ 
and potentially an attenuation of the inward rectifying current (Kir) which helps to 
buffer extracellular K+.  Elevated extracellular glutamate and K+ could enhance 
glutamate receptor activation and neuronal excitability, possibly pre-disposing the 
aged hippocampus to synchronous neuronal firing and excitotoxicity.   
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 What if the aged Kir was inherently disrupted like in TLE patients?  
Inappropriate buffering and the subsequent increase in extracellular K+ can 
reverse transporter function, and actually result in the release of glutamate from 
astrocytes.  Again, elevated extracellular glutamate and K+ could enhance 
neuronal excitability while increased glutamate could result in over-activation of 
ionotropic receptors leading to excitotoxicity. Due to the ability of high levels of 
extracellular K+ to depolarize neurons in both scenarios, auto-regulation of pre-
synaptic glutamate release via mGluRs would potentially fail to attenuate 
glutamate release even though extracellular levels would be increasing. 
 In theory, 4-AP could facilitate dysregulation already present in the aged 
hippocampus by potentiating the inappropriate buffering of K+ (first scenario), or 
paradoxically fail to produce activity in aged rats with inherently disrupted K+ 
regulation which is the result of loss of Kir channels (second scenario).  Our data 
indirectly support that Kir channels are intact in the aged hippocampus; however 
this is not an indication of proper function, especially when extracellular 
glutamate levels are elevated.  In addition to therapeutic strategies aimed at 
regulating glutamate levels, the pharmacological facilitation of proper K+ buffering 
may reduce the occurrence and severity of SE in elderly.  These studies do not 
allow for conclusions to be drawn about transporter function in the aged 
hippocampus.  Prior studies actually demonstrated that transporter function may 
be increased in the aged DG.  Based on the present study, we can conclude that 
glutamate neurotransmission is severely disrupted during SE and that age-
associated increases in tonic glutamate levels in the extracellular space, 
regardless of origin, correlate with increased severity of SE.          
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Figure 4.1 Tonic Glutamate in the Trisynaptic Circuit of Awake                
Rats During Aging 
 
Compared to young animals (8.4 ± 1.1 µM), tonic glutamate levels were 
significantly elevated in the late-middle aged (16.3 ± 3.0 µM, p < 0.05) and aged 
(16.7 ± 3.2 µM, p < 0.05) hippocampal formation.  Each symbol represents an 
individual animal.  As is typical in aging studies, data variability increases with 
age, but the data are normally distributed (young, p = 0.23; late middle-aged, p = 
0.41; aged, p = 0.19, D’Agostino and Pearson omnibus normality test). 
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Figure 4.2 Traces from ‘Glutamate-sensitive’ and Sentinel MEA Recording 
Sites During Status Epilepticus in the Awake Rat 
 
Representative traces for the entire duration of Day 4 recordings in CA1.  Local 
application of glutamate (5 mM, triangles) produces a robust response on the 
glutamate-sensitive recording site (black trace) and no response on the sentinel 
recording site (grey trace).  High levels of glutamate following exogenous 
application are rapidly cleared and do not result in spontaneous release events 
(A).  Local 4-AP (arrow = low dose; hashed arrow = high dose) produces a large 
transient increase in glutamate, followed by spontaneous synchronized 
glutamate release events that only appear on the glutamate-sensitive sites (B 
and C).  Any movement artifact from WDS can be removed by self-referencing.      
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Figure 4.3 Spontaneous Glutamate Release During Status Epilepticus Is 
TTX-sensitive  
 
Self-referenced recording showing that glutamate release events during 4-AP-
induced SE are halted following local application of TTX (100 µM, 1 µL, arrow).  
TTX also halted the expression of WDS. 
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Figure 4.4 Spontaneous Glutamate Release After Low-dose 4-AP 
 
Self-referenced recordings showing highly synchronous glutamate release 
events in CA1 following intrahippocampal injection of 4-AP (5.25 nmol).  Left: 
Spontaneous glutamate activity during WDS behavior.  Insets: Magnification of 
traces showing amplitude and period of glutamate peaks across age groups.  
Age did not significantly affect any of the behavioral or glutamate release 
characteristics during SE induced by low dose 4-AP (p > 0.05 for all parameters).    
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Figure 4.5 Spontaneous Glutamate Release After High-dose 4-AP 
 
Self-referenced recordings showing glutamate release events in CA1 following 
intrahippocampal injection of 4-AP (21 nmol).  Left: Spontaneous glutamate 
activity during wet-dog shaking behavior.  Insets: Magnification of traces showing 
amplitude and period of glutamate peaks across age groups.  Aged rats 
experienced a longer duration of status epilepticus (105 ± 15 min.) than young 
rats (55 ± 10 min., p < 0.01) and late-middle aged rats (66 ± 9 min., p < 0.05).  
Related to the SE duration, total glutamate release events were also higher in 
aged rats (105.0 ± 14.8) than young rats (55.0 ± 10.3), p < 0.05.    
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Figure 4.6 Tonic Glutamate Predicts Status Epilepticus Outcomes 
 
Regression analysis showed that higher levels of pre-status basal glutamate 
(seen in late-middle aged and aged animals) resulted in significant increases in 
A) status duration (p < 0.01), B) average WDS/ 5 min. (p < 0.001), C) maximum 
WDS/ 5 min. (p < 0.001),  and E) average glutamate peak size after low-dose 4-
AP (p < 0.05).  Total numbers of glutamate release events (D) and release 
periodicity (F) were not affected by pre-SE basal glutamate levels (p > 0.05). 
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Figure 4.7 Quantity and Size of Glutamate Release Events Correlates with 
Behavior During Status Epilepticus 
 
Regression analysis showed after both the low and high doses of 4-AP, the total 
number of glutamate release events significantly correlated with the total number 
of WDS (p <0.05).  The average size of the glutamate peaks predicted the 
average WDS/ 5 min. after the low dose (p < 0.05), but this relationship was not 
significant after the high dose (p > 0.05).     
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Figure 4.8 Pre- and Post-status Epilepticus Tonic Glutamate Levels in CA1 
 
Basal glutamate concentrations obtained before (black) and after (grey) SE 
showed that exposure to 4-AP and the subsequent induction of SE did not 
significantly change tonic glutamate in any age group (p > 0.05, two-way 
ANOVA).  Pre-SE vs. post-SE: young, 6.2 ± 1.0 µM vs. 7.8 ± 1.5 µM; late-middle 
aged, 9.1  ± 3.1 µM vs. 7.7 ± 2.7 µM; aged, 7.6 ± 3.8 µM vs. 9.1± 5.9 µM. 
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Figure 4.9 Real-time Amperometry vs. Microdialysis 
 
A) Comparisons of a self-referenced amperometric glutamate recording during 4-
AP-induced SE (grey trace) to a hypothetical microdialysis recording (black trace) 
with a dialysate fraction collection period of 5 minutes (squares).  B)  Due to the 
temporal resolution, traditional microdialysis is not capable of measuring 
spontaneous glutamate release events during SE.  C)  Second-by-second 
glutamate measurements (circles) capture fast dynamic glutamate release and 
clearance processes. 
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 Table 4.1 Tonic Glutamate in the Hippocampus of Unanesthetized Rats 
[µM] 
 
 
 
 
DG CA3 CA1 
 
Combined 
Hippocampal 
Glutamate 
Young 7.9 ± 1.4 11.7 ± 2.9 6.2 ± 1.0 8.4 ± 1.1 
 
    
Late-middle Aged 17.5 ± 5.6 23.6 ± 5.3 9.1 ± 3.1 16.3 ± 3.0 
 
    
Aged 17.3 ± 12.6 22.2 ± 7.1 10.7 ± 4.3 16.2 ± 3.3 
 
    
Comparison 
Across Age 
Groups 
(One-way ANOVA) 
p = 0.13 p = 0.14 p = 0.60 *p = 0.038 
Y < LMA, p < 0.05 
Y < A, p < 0.05 
All values represent the mean ± S.E.M. 
Young (Y, 3-6 months), DG: n = 8; CA3: n = 5; CA1: n = 6 
Late-middle Aged (LMA, 18 mo.), DG: n = 6; CA3: n = 5; CA1: n = 6 
Aged (A, 24 mo.), DG: n = 7; CA3: n = 6; CA1: n = 6 
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Table 4.2 Behavioral Characteristics During 4-AP-Induced                    
Status Epilepticus 
 
 
 
 
Young 
Late-
middle 
Aged Aged Dose-Effect Age-Effect 
SE Duration 
   ***p < 0.0001 *p < 0.05 
(minutes) 
     
low dose 8.3 ± 2.5 22.5 ± 5.1 30.0 ± 11.4   
high dose 55.0 ± 10.3 65.8 ± 8.6 105.0 ± 14.8  A > Y, **p < 0.01 
    
 
 A > LMA,  
*p < 0.05 
Average WDS/  
5 min. 
   
***p < 0.0001 p > 0.05 
low dose 1.7 ± 0.4 2.7 ± 0.7 3.3 ± 1.4   
high dose 9.5 ± 2.6 14.0 ± 4.3 14.2 ± 2.0   
Max. WDS/  
5 min. 
   
***p < 0.0001 p > 0.05 
low dose 2.3 ± 0.7 7.5 ± 3.6 10.6 ± 6.3   
high dose 22.8 ± 6.8 30.5 ± 8.2 31.2 ± 2.9   
All values represent the mean ± S.E.M. 
Young (3-6 months), n = 6 
Late-middle Aged (18 mo.), n = 6 
Aged (24 mo.), n = 5 
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Table 4.3 Glutamatergic Activity During 4-AP Induced Status Epilepticus 
 
 
 
 
Young 
Late-
middle 
Aged Aged Dose-Effect Age-Effect 
Latency to  
      
Spontaneous 
Release 
  
 
p > 0.05 p > 0.05 
(minutes) 
     
low dose 1.4 ± 0.8  2.3 ± 0.5 2.3 ± 0.6   
high dose 1.3 ± 0.4 2.0 ± 0.8 2.5 ± 0.7   
Glutamate 
     
Release Events 
 
  
 ***p < 0.0001 *p < 0.05 
low dose 7.8 ± 3.3 21.8 ± 7.2 35.6 ± 15.9   
high dose 66.2 ± 10.1 89.3 ± 10.3 111.1 ± 6.8 
 
  A > Y, 
**p < 0.01 
Ave. Peak Size 
   p > 0.05 p > 0.05 
(µM) 
     
low dose 1.3 ± 0.6 1.9 ± 0.4 2.1 ± 0.5   
high dose 1.9 ± 0.6 2.8 ± 0.4 1.5 ± 0.2   
Release Periodicity 
   p > 0.05 p > 0.05 
(seconds) 
     
low dose 109 ± 49 87 ± 25 58 ± 7   
high dose 49 ± 2 44 ± 3 56 ± 6   
All values represent the mean ± S.E.M. 
Young (3-6 months), n = 6 
Late-middle Aged (18 mo.), n = 6 
Aged (24 mo.), n = 5 
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Chapter Five:  Real-time Glutamate Measurements in the Putamen of 
Awake Rhesus Monkeys Using an Enzyme-based Human        
Microelectrode Array Prototype 
 
Introduction 
 
 Chapter Four highlighted the potential to use tonic hippocampal glutamate 
levels as a biomarker for the identification of populations at high-risk for status 
epilepticus-associated morbidity.  Also, dysregulation of glutamatergic 
neurotransmission during seizure, manifesting as repeated spontaneous 
synchronized glutamate release events, was recognized as a novel marker of 
ongoing seizure.  Based upon the potential to translate these findings into 
clinically-oriented initiatives, we began the development of microelectrode array 
(MEA) technology for use in humans.   
The gold standard for in vivo monitoring of neurochemistry has been 
microdialysis.  In addition to the complexity of the procedure, the most limiting 
characteristic of microdialysis has been the time resolution of the method, which 
acts like a low-pass filter when sampling chemicals in the extracellular space.  
This is especially important when measuring glutamate due to its rapid release 
and clearance processes.  Researchers utilizing microdialysis techniques have 
explored many ways of improving the sampling of dialysates.  One of the most 
popular techniques has been the coupling of microdialysis with on-line enzymatic 
conversion of analytes such as glutamate, followed by amperometric or 
fluorescence detection (Obrenovitch and Zilkha, 2001; Galvan et al., 2003; 
Zhang and Mao, 2005; Jin et al., 2008).  Using similar principles, we have 
developed and extensively characterized a more streamlined approach using 
ceramic-based MEAs with glutamate oxidase (GluOX) cross-linked to the 
platinum recording surfaces coupled with real-time amperometric detection for  
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sub-second (2 Hz) in vivo measurements of glutamate (Burmeister et al., 2002; 
Pomerleau et al., 2003).   
 Monitoring of extracellular glutamate has been an area of interest for 
neurosurgeons and neuroscientists trying to understand a wide variety of 
pathological processes that are believed to have an excitotoxic component like 
epilepsy and traumatic brain injury (Hillered et al., 2005).  The goal of 
intracerebral microdialysis monitoring is to detect impending pathological events 
before they are clinically evident; therefore, time resolution is absolutely critical.  
The commercially available ISCUSflex clinical microdialysis analyzer (CMA 
Microdialysis, Solna, Sweden) has a 60 second sampling rate, but again a faster 
time resolution is needed for certain applications (Valadka et al., 1998; Reinert et 
al., 2000; Schulz et al., 2000).  Despite several studies over the last 15 years 
reporting on the use of microdialysis in patients, no examples of clinical 
management guidelines based upon glutamate exist (Hillered et al., 2005) which 
may be related to the limitations of the microdialysis method. 
 The size, structure and function of non-human primate (NHP) brains have 
made them very desirable for neuroscientists aiming to closely approximate the 
human CNS in their investigations (for review see Bradberry, 2000).  Despite the 
advantages over rodents, few studies report on glutamate measurements in the 
NHP brain (Graham et al., 1989; Kling et al., 1993; Yin et al., 1997; Enblad et al., 
2001; Kodama et al., 2002; Galvan et al., 2003; Quintero et al., 2007; Zhao et al., 
2007).  Using the enzyme-based MEA recording technology, we have extensively 
investigated glutamate regulation in the mammalian CNS (Pomerleau et al., 
2003; Nickell et al., 2005; Day et al., 2006; Nickell et al., 2007; Quintero et al., 
2007; Stephens et al., 2009).  Recently, we have begun adapting the basic-
science MEA for potential clinical use.  Our recording technology has a distinct 
advantage in temporal resolution compared to currently utilized cerebral 
microdialysis techniques.  Our ability to monitor glutamate in real-time may 
advance the development of clinical decision algorithms based upon glutamate 
fluctuations in the extracellular space to assist care-providers in determining the 
clinical course of patients with traumatic brain injury or sub-arachnoid 
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hemorrhage, and may assist neurosurgeons during epilepsy surgery (see 
Stephens et al., 2008). 
 In these studies we used our human MEA prototype (Spencer-Gerhardt-2 
(SG-2), ADTECH Medical Instrument Corp., Racine, WI) in awake NHPs to 
determine glutamate levels in the putamen.  These studies contribute information 
to the literature about the NHP basal ganglia, which is known to be involved in a 
variety of pathological processes including Parkinson’s disease, Huntington’s 
diseases and psychiatric disorders (Kreitzer and Malenka, 2008), and evaluate 
the abilities of our SG-2 MEAs to target sub-cortical structures and measure 
glutamate in a clinical setting.  We also performed functional assessments of SG-
2 MEAs post-sterilization, setting the stage for future studies in humans. 
 
Methods 
 
 Please refer to Chapter Two for a detailed description of animal care, 
electrode preparation, sterilization procedure, electrode calibration, amperometric 
recording technique, and methodology for measuring and comparing tonic 
glutamate neurotransmission in the NHP putamen. 
 
Results 
 
 In the batch of SG-2 MEAs that had been coated with the GluOX solution 
11 months prior to sterilization, 10 out of 16 (63%) had at least one recording site 
that retained 1 pA/µM glutamate sensitivity or greater.  Of these 10 functional 
SG-2 MEAs, 8 (80%) actually had 3 or 4 recordings sites that remained sensitive 
to glutamate post-sterilization.  The average sensitivity of the functional recording 
sites was 5.6 ± 0.7 pA/µM (n = 29), well above the threshold for in vivo use.  The 
average LOD was 0.37 ± 0.09 µM.  In the batch of SG-2 MEAs that had been 
coated with the GluOX solution one month prior to sterilization, 14 out of 16 
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(88%) had at least one recording site with 1 pA/µM glutamate sensitivity or 
greater.  Again, almost all 14 of the functional SG-2 MEAs actually had multiple 
sites that retained the ability to measure glutamate (12/14 (86%) had 3 or 4 
functional sites).  The average glutamate sensitivity of the functional recording 
sites was 7.5 ± 0.7 pA/µM (n = 47).  The average LOD was 0.47 ± 0.14 µM.  
Though the mean sensitivity of the functional recording sites was greater in the 
batch prepared one month prior to sterilization, the difference was not significant 
(sensitivity p = 0.06, (t = 1.9, df = 74)).  Likewise, there was no significant 
difference in the LOD of the two batches (p = 0.58, t = 0.57, df = 74), indicating 
that enzyme coated SG-2 MEAs have a good shelf life, and can withstand 
sterilization (Table 5.1).   
 The primary objective of these studies was to measure extracellular 
glutamate concentrations in the putamen of unanesthetized NHPs using the 
newly developed SG-2 MEA human prototype (Table 5.2).  With self-referencing 
recording techniques (Day et al., 2006; Quintero et al., 2007) we were first able 
to determine tonic glutamate levels at a dorsal position in the putamen (NHP 1 = 
25.4 µM; NHP 2 = 6.9 µM; NHP 3 = 9.8 µM) (Figure 5.1).  As the SG-2 MEA was 
progressed 2 mm to a more ventral position in the putamen, we measured a 
robust increase in extracellular glutamate followed by clearance and stabilization 
of glutamate levels after approximately 15 min.  This increase is probably due to 
ruptured glutamate terminals.  Tonic glutamate levels at the ventral depth were: 
NHP 1 = 34.2 µM; NHP 2 = 10.6 µM; NHP 3 = 11.5 µM.  In the follow-up 
experiments conducted four months later, glutamate levels were as follows: 
dorsal: NHP 1 = 15.1 µM; NHP 2 = 4.9 µM; NHP 3 = 7.7 µM; ventral: NHP 1 = 
12.6 µM; NHP 2 = 5.3 µM; NHP 3 = 5.6 µM).  There was not a significant 
difference between tonic glutamate measurements obtained in the dorsal 
recording position compared to the ventral position (p = 0.38 (t = 0.97, df = 5).  
The glutamate measurements recorded on the follow-up day of experimentation 
were significantly lower than the first measurements (p = 0.047 (t = 2.6, df = 5).  
No medical complications were reported throughout the duration of the study, 
which gave a preliminary indication of SG-2 MEA safety.   
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 Perhaps the most interesting findings from these studies were the rapid 
fluctuations of glutamate in the extracellular space of the putamen.  We were 
able to capture dynamic fluctuations because of the fast temporal resolution (2 
Hz) of the glutamate measurements obtained with the FAST16 instrument. We 
arbitrarily chose a 60 second window 10 minutes after the lowering of the SG-2 
MEA to the ventral depth in the putamen to compare recordings from each 
animal (Figure 5.2).  A qualitative assessment showed the youngest NHP had 
the most spontaneous activity with some of the rapid release events resulting in 
changes in extracellular glutamate of 2 µM or greater.  This is remarkable 
because the youngest animal also had the highest tonic glutamate levels.  It is 
important to note that these events were not synchronized and showed no 
rhythmic periodicity.  We can be sure these dynamic changes in extracellular 
glutamate are not artifacts because of our self-referenced recording technique.  
Self-referencing removes background noise and artifact whether electrical or due 
to movement of the animal.  Though we do not have enough subjects in this 
study to make a statistical comparison across animals, we are very encouraged 
about the potential of this high-temporal resolution recording technique for use in 
monitoring glutamate in clinical applications where rapid and dynamic changes in 
extracellular glutamate may predict outcome or guide intervention, especially in 
light of the spontaneous release activity recorded during status epilepticus in rats 
(Chapter Four).        
 
Discussion 
 
 These studies demonstrated that we can obtain real-time measurements 
of extracellular glutamate in awake non-human primates using enzyme-based 
MEA technology coupled to amperometric recordings with a design that has been 
adapted for humans (SG-2).  Through a chronically implanted access cannula, 
we obtained tonic and phasic glutamate measurements at two different depths in 
the putamen and repeated the study four months later.  The temporal resolution 
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(2 Hz) of these measurements allowed us to record dynamic oscillations in 
extracellular glutamate, which to our knowledge has never been reported.  We 
showed that sterilization did not significantly compromise the integrity and 
function of the enzyme/protein layers applied to SG-2 MEAs for the detection of 
glutamate.  We also showed that the SG-2 MEAs have a shelf-life of at least 11 
months. 
 
SG-2 MEAs Can Reliably Measure Glutamate in a Clinical Setting  
 The tonic glutamate measurements in our youngest NHP animal agreed 
with a prior study from Galvan et al. (2003) that reported ~29 µM glutamate in the 
putamen of awake juvenile (3-4 kg) Rhesus monkeys.  Glutamate levels 
appeared lower in the older animals. We have previously shown age-associated 
alterations in glutamate regulation in the striatum of rodents (Nickell et al., 2005; 
Nickell et al., 2007), but the current study was not designed to determine if a 
statistical difference in tonic glutamate concentrations existed across age groups.  
Based upon this study, future studies of glutamate regulation in the striatum 
should also closely examine dynamic transients in the glutamate measurements.  
The youngest NHP appeared to have larger magnitude peaks and dips in 
glutamate concentration compared to the older animals.  This type of activity 
simply cannot be measured with microdialysis techniques, and potentially could 
provide a completely novel parameter to assess glutamatergic tone in vivo.  
 Due to the small size of the recording sites, the SG-2 MEAs can 
discriminate differences in extracellular glutamate in NHP brain areas separated 
by as little as 500 µm (Quintero et al., 2007).  We measured tonic glutamate in 
the putamen at two depths separated by a 2 mm dorsal-ventral progression of 
the SG-2 MEA.  The measurements obtained at the two depths were not 
statistically different, but did highlight the ability of the SG-2 MEAs to target 
different brain layers and obtain a stable basal glutamate measurement much 
faster than the most recent report in the literature using microdialysis to measure 
glutamate in the NHP striatum (SG-2 MEA = 20-30 min. baseline vs. 
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microdialysis = 60 min. baseline (Galvan et al., 2003)).  Shortening the delay-to-
stabilization of the glutamate measurements indicates that our technology could 
potentially sample from at least twice as many brain areas compared to 
microdialysis in a fixed amount of time.  
 The NHPs used in our studies were maintained in our animal care facility 
for four months after the first experiment day, and no adverse events were 
reported.  This is a preliminary indication that the SG-2 MEAs can be safely used 
in vivo.  Compared to the first day, tonic glutamate measurements in the 
putamen were significantly lower after the four month maintenance period.  We 
believe this is most likely due to presence of the chronic access cannula, which 
may have caused the formation of scarring in the areas targeted by the SG-2 
MEA.  We have previously shown that our MEAs cause minimal damage and 
scarring in the surrounding tissue, even in chronic implants (Rutherford et al., 
2007).  In the future, we would like to utilize the methodology proposed by 
Kolachana et al. (1994) which via attachment of a ‘guide holder’ to the skull of 
rhesus monkeys, repeated studies can be performed in ‘fresh’ or ‘experienced’ 
brain parenchyma without the need of indwelling cannulae or multiple surgeries.     
 
SG-2 MEAs Tolerate Sterilization 
 The commercially available ISCUSflex clinical microdialysis analyzer 
(CMA Microdialysis, Solna, Sweden) uses kinetic enzymatic conversion followed 
by colorimetry to measure glutamate in dialysate samples obtained once every 
60 seconds.  Our recording technology bypasses the collection of samples and 
detects glutamate via enzymatic conversion at GluOX-coated recording sites on 
an indwelling MEA.  Coupled to high speed amperometry, our MEAs are able to 
measure glutamate in vivo on a second-by-second time scale.  Adapting our 
basic science MEA technology for potential clinical use necessitated the 
development of a sterilization protocol.  With these studies we have determined 
that the performance of the SG-2 MEA remains well above the functional 
threshold for detection of glutamate following electron beam sterilization.  
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Additionally, the SG-2 MEAs have a shelf-life of at least the duration of the study, 
11 months, which is very important to the logistics of distributing MEAs for clinical 
use.  We have initiated development of a clinical calibration protocol using sterile 
reagents.  Preliminary results indicate that there is no difference in the functional 
parameters (e.g. glutamate sensitivity) of MEAs when calibrated with sterile 
verses the non-sterile reagents (see Appendix).  We are currently performing a 
functional characterization of enzyme/protein coated SG-2 MEAs that have also 
been coated with Nafion  to determine the effects of sterilization on the anion 
repelling properties of Nafion.               
 
Advantages of Amperometric Recordings Using Enzyme-based SG-2 MEAs 
 Using enzyme-based MEAs for in vivo amperometric detection of 
glutamate has several advantages over the current gold standard technique, 
microdialysis.  To our knowledge, the fastest sampling rate for glutamate 
measurements obtained with microdialysis in a laboratory setting is 1 second, but 
the diffusional exchange of analytes across the microdialysis membrane results 
in a delay of several seconds (for review see Kennedy et al. 2002).  Also, Rossell 
et al. (2003) reported that based on their data in awake-behaving rats, glutamate 
release and clearance events were not adequately measured with 1 Hz 
resolution because these events seemed to occur faster.  We routinely measure 
glutamate at 2 Hz.  As demonstrated by our measurements of dynamic 
fluctuations in extracellular glutamate in unanesthetized NHPs, our temporal 
resolution is superior for monitoring the rapid events associated with 
glutamatergic neurotransmission.   
 Microdialysis procedures can be laborious and time consuming, especially 
when incorporating adaptations to improve temporal resolution (Rossell et al., 
2003).  Major contributors to this are procedures for calibrating microdialysis 
probes and determining probe recovery rates (Hillered et al., 2005).  Calibration 
of SG-2 MEAs is very straight-forward, and requires only 20 minutes to complete 
(Burmeister et al., 2002; Pomerleau et al., 2003).  Microdialysis experimental 
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protocols require tubing and pumps to flow artificial cerebral spinal fluid (aCSF) 
through the microdialysis probe which can introduce mechanical interference to 
measurements made by on-line detection methods that improve the temporal 
resolution (e.g. fluorometry).  Even though this may be believed to be negligible 
(Galvan et al., 2003), our self-referencing technique allows for the removal of 
background noise which in a clinical scenario could arise from a variety of 
sources including patient movement and the myriad electrical devices.  Also the 
microdialysis procedure may have additional confounders like the use of room-
temperature aCSF and air-saturated solutions (with markedly different O2 and 
CO2 saturations than the interstitial fluid) that can affect neurotransmission 
(Hillered et al., 2005).  We avoid this by directly measuring glutamate in the 
extracellular space, without the exchange of fluid, which minimizes disruption of 
the extracellular space and leaves the microenvironment around the MEA intact.        
 Attached microelectrodes on microdialysis probes for dual 
electrophysiological and electrochemical recordings have been used to study a 
number of brain processes including epilepsy and TBI (Obrenovitch and Zilkha, 
1995; During and Spencer, 1993; Fried et al., 1999; Alves et al., 2005).  It has 
recently been reported that our enzyme-coated MEAs for electrochemical 
measurements can simultaneously measure electrophysiological currents in vivo 
(Zhang et al., 2009).  Combining information about the electrical activity of 
neurons and the resulting chemical environment in the extracellular space can 
provide a more comprehensive understanding of pathological processes and 
response to injury.   
 The spatial resolution of our MEAs (microns) allows us to obtain 
information closer to the synapse than microdialysis probes which are millimeters 
in length.  The size of microdialysis probes not only lowers the spatial resolution 
of the measurements, but is also a substrate for damage to the surrounding 
tissue.  It has been reported that microdialysis probes extensively injure brain 
parenchyma with damage extending up to 1.4 mm from the implant site (Clapp-
Lilly et al. 1999).  In contrast, chronic studies with our MEAs showed minimal 
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damage around the implant site, ranging 50 to 100 microns after eight weeks in 
vivo (Rutherford et al., 2007).   
 Currently, a clear limitation of the SG-2 MEA is the ability to measure only 
one analyte at a time, whereas microdialysis allows for detection of several 
analytes.   Though our standard MEAs have four platinum sites, arrays with up to 
16 recording sites have been fabricated.  To date, enzyme coatings have been 
developed to measure glutamate, choline, acetylcholine, lactate, and glucose 
(Burmeister et al., 2004; Burmeister et al., 2008).  Electroactive compounds such 
as dopamine, norepinephrine, and O2 can also be measured (Burmeister et al., 
2004).  In the future we hope to be able to measure multiple analytes in vivo with 
a single MEA, and provide a real-time compositional analysis of the extracellular 
fluid. 
 
Clinical Applications for Enzyme-based MEAs 
 Many studies using intracerebral microdialysis have shown that glutamate 
may be an important indicator of clinical course following brain injury.  In acute 
focal ischemia imposed during the resection of brain tissue, patients have shown 
increased glutamate levels (Hillered et al., 1990; Kanthan et al., 1995) that are 
proportional to the extent of tissue resected, i.e. the duration of the ischemia 
(Kanthan et al., 1996).  This has indicated a potential use for monitoring 
glutamate levels to predict intra-operative hypoxia (Mendelowitsch et al., 1998), 
but study outcomes have not been consistently positive (Hutchinson et al., 2000; 
Kett-White et al., 2002).  The prospects for glutamate as a diagnostic tool have 
been better in subarachnoid hemorrhage (SAH).  Increased glutamate levels 
have preceded and predicted the deterioration of SAH patients (Unterberg et al., 
2001; Sarrafzadeh et al., 2002).  Monitoring glutamate levels, known to be very 
important to secondary injury cascades, for management of traumatic brain injury 
patients is also promising (for review see Hillered et al., 2005).  Though 
glutamate, and other analytes such as lactate, glucose and O2, show potential as 
markers of injury and clinical course, no medical guidelines are based upon 
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cerebral monitoring with microdialysis (Hillered et al., 2005).  For the reasons 
explained above, MEAs could monitor relevant compounds in the CNS faster 
than microdialysis while causing less damage than microdialysis probes to 
already injured tissue.  We believe this may give care-providers a more accurate 
analysis of the brain’s chemical profile, and facilitate the development of clinical 
algorithms based upon neurochemistry.  
 An especially novel application of MEAs may be in epilepsy surgery.  
Resection of diseased brain tissue has provided favorable outcomes for some 
patients with seizures refractory to medication; however, patients without a 
discrete focus of seizure activity or with foci in eloquent brain regions have 
remained difficult to treat.  Inadequate delineation of the normal brain-
epileptogenic zone interface has been the major contributor to poor surgical 
results in these patients, despite advances in multimodality image-guided surgery 
and brain function testing (Murphy et al., 2004).  We believe MEAs could be used 
as a supplemental diagnostic to provide neurosurgeons with a real-time 
measurement of extracellular glutamate, which is known to be elevated in seizure 
foci (reviewed by Eid et al., 2008).  Also, the unique synchronized glutamate 
release events shown to occur during status epilepticus in rats could certainly 
identify seizing neurons from adjacent dormant brain tissue (Chapter Four).  The 
spatial resolution of the MEA glutamate measurements could improve accuracy 
of the margin of excision for seizure foci from millimeters to micrometers, which is 
absolutely critical when performing excision surgery (Murphy et al., 2004).  In 
addition, providing neurosurgeons and neuroscientists with a novel tool to 
investigate the role of glutamate neurotransmission in human seizures, SAH, 
ischemia and TBI could possibly lead to the development of new medications 
and interventions for difficult to treat neurologic patient populations. 
 
 
 
 
 
 102 
 
Portions of this work have been previously published: 
 
M.L. Stephens, F. Pomerleau, P. Huettl, G. A. Gerhardt and Z. Zhang.  Real-time 
glutamate measurements in the putamen of awake rhesus monkeys using an 
enzyme-based human microelectrode array prototype.  Journal Neurosci. 
Methods (submitted, 2009) 
 
Copyright © Michelle Lee Stephens 2009  
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Figure 5.1 Basal Glutamate Measurements in the NHP Putamen  
 
Traces show current measured on ‘glutamate-sensitive’ recording site (solid line) 
and sentinel site (dashed line).  Arrow indicates 2 mm ventral progression of the 
SG-2 MEA in the putamen. Note the robust increase in glutamate, most likely 
due to disruption of terminals during MEA movement.  Self-referencing yields 
basal glutamate measurements at depth 1 (GluRest1) and depth 2 (GluRest2).  
Recordings are four months apart.  The youngest NHP appears to have the 
highest basal glutamate levels. 
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Figure 5.2 Dynamic Glutamate Oscillations in the NHP Putamen  
 
Self-referenced recordings show dynamic glutamate oscillations at the second 
recording depth.  Recordings are four months apart.  The youngest NHP appears 
to have the most oscillatory behavior.  The attenuation of oscillations in the 
follow-up recordings could be due to could be damage from the chronically 
implanted guide cannula, or might indicate positioning of the SG-2 MEA in  a 
slightly different location than the first recordings.   
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Table 5.1 Functional Analysis of SG-2 MEAs Post-sterilization 
 
Batch Functional 
/ Total 
% Average 
Sensitivity 
(mean ± SEM) 
Average 
LOD 
(mean ± 
SEM) 
 
 
   
Coated with GluOX  
1 month prior to sterilization 
10 / 16 63 5.6 ± 0.7 pA/µM 0.37 ± 0.09 
µM 
     
     
     
     
Coated with GluOX  
11 months prior to 
sterilization 
14 / 16  88 7.5 ± 0.7 pA/µM 0.37 ± 0.09 
µM 
     
     
     
t-test (1 mo. vs. 11 mo.)   p = 0.06 p = 0.57 
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Table 5.2 Tonic Glutamate Measurements in the NHP Putamen 
 
Animal Depth  First 
Recording 
(µM) 
Follow – up 
Recording † 
(µM) 
 
 
   
NHP 1 (11 y.o.) 
          1             25.4               15.1 
 
 
          2             34.2               12.6 
 
NHP 2 (19 y.o.) 
 
          1 
 
             6.9 
 
              4.9 
           2             10.6               5.3 
     
    
NHP 3 (21 y.o.) 
          1              9.8               7.7 
           2             11.5               5.6 
    
    
† Follow–up recordings were significantly lower compared to the first recordings  
(Paired t-test for repeated measures, p = 0.047)  
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Conclusions 
  
Several interesting things happened in the news media while I was 
finishing this dissertation.  Just a few days before I distributed this document to 
my committee members for review, Newsweek’s cover story was ‘The Mystery of 
Epilepsy, Why We Must Find A Cure’.  I also heard a report on National Public 
Radio about the rapid rate at which the population of the world is aging, and how 
this is going to affect every aspect of life, as we as a society collectively try to 
care and provide for elderly people.  To me, this is additional validation that the 
questions addressed in this dissertation are extremely timely and relevant.      
 I believe the work I completed as a graduate student has really contributed 
something of worth to the aging and epilepsy research communities.  I have 
potentially revealed a terrible irony during aging.  My studies in the rodent 
hippocampus revealed that approximately one-third of late-middle aged and aged 
rats have elevations in their tonic extracellular glutamate levels.  This is the same 
proportion of the population that has been shown to perform as well as younger 
rats in learning and memory tasks.  Functional testing of the rodents used for 
glutamate regulation studies in the hippocampus is a critical piece of information I 
was not able to collect at the time of studies; however, I feel comfortable 
hypothesizing that animals with higher levels of extracellular glutamate have 
developed a mechanism to compensate for synaptic loss in the hippocampus 
during aging, rendering them functionally ‘young’.  The irony I mentioned is that 
these same animals are predisposed to have longer and more severe seizures.  
At this point, I cannot be sure at what age tonic hippocampal glutamate levels 
start to rise.  Future studies should incorporate a middle-aged experimental 
group (12 months old) to help address this question.   
 My work focused on understanding glutamate dysregulation during 
prolonged seizures, termed status epilepticus, has the potential to really change 
the way researchers and clinicians have traditionally viewed glutamate’s role in 
seizure.  It is now clear that seizing hippocampal neurons display very rhythmic 
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glutamate neurotransmission, resulting in dynamic rapid glutamate release and 
synaptic spillover approximately once every thirty seconds.  In my studies, the 
overall tonic glutamate levels did not change during status epilepticus, but rather 
were punctuated by spontaneous phasic glutamate release events.  This is in 
stark contrast to previous beliefs that altered glutamate neurotransmission during 
seizure led to slow, steady and very large increases in extrasynaptic glutamate 
levels (several hundred times the tonic baseline).  The spontaneous glutamate 
release events were extremely sensitive to the Na+ channel blocker, TTX.  This 
could explain why anti-epileptic drugs with mechanisms of action at Na+ channels 
work.  Based upon my studies, I believe development of novel therapeutics  
should continue to focus on ways to inhibit seizure-associated spontaneous 
glutamate release.  Also, the magnitude of the release events significantly 
correlated with the severity of the seizure-associated convulsive behavior.  
Perhaps when larger boluses of glutamate are released during the spontaneous 
neurotransmission, inappropriate glutamate receptor activation potentiates the 
severity of behavior.  Drug developers should also explore ways to minimize 
excessive receptor activation.  Potentially the most important question remains 
‘how do we minimize risk for seizure-related morbidity (i.e. lower the tonic 
glutamate levels), while not compromising hippocampal function in elderly 
populations?’.   
 Though rodents are an excellent tool for studying the central nervous 
system, the fact remains that to really understand human biology, we must study 
glutamate in the human brain.  Patients with refractory epilepsy that have been 
identified as candidates for surgical foci resection are the ideal patient population 
in which to pioneer human glutamate recordings with microelectrode arrays 
(MEA).  A large part of my efforts as a graduate student were directed toward the 
development and testing human MEA technology.  At the completion of this 
dissertation, the human MEA prototype (Spencer-Gerhardt-2 MEA (SG-2)) was in 
the ‘final post-sterilization validation studies’ phase of development, with hopeful 
imminent progression to obtainment of a FDA Investigational Device Exemption 
and IRB approval.  As an MD/PhD student, I have two more years of clinical 
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training at the University of Kentucky.  I hope the first human glutamate 
recordings occur before I graduate.  If a unique glutamatergic neurotransmission 
profile exists in seizure foci of humans, like what I have shown in rodents, MEAs 
could provide neurosurgeons with a novel supplemental diagnostic for the 
identification of diseased neurons during surgery.  Initially, I believe information 
gained from human glutamate recordings in seizure foci will be of most value for 
validating animal models of epilepsy.  Eventually, MEAs could be expanded for 
second-by-second monitoring of extracellular glutamate in stroke, subarachnoid 
hemorrhage and traumatic brain injury patients which could push the integration 
of glutamate measurements into clinical decision-making algorithms.                     
 
Copyright © Michelle Lee Stephens 2009
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Appendix: Additional Considerations for Clinical Glutamate Recordings 
 
 The tonic glutamate data presented in Chapters Three and Four 
emphasize the need to further characterize the affects of anesthesia on basal 
glutamate.  This is especially important for future human studies.  The first 
human recordings are currently being planned, and will proceed in patients 
referred for temporal lobe resection for the treatment of persistent epilepsy.  
Though patients are sometimes awake during certain portions of a resection 
surgery when brain areas need to be evaluated for essential-function (i.e. 
speech, motor movement) prior to removal, measurements with glutamate-
sensitive MEAs will most likely occur while patients are under general 
anesthesia.   
 Isoflurane is a halogenated hydrocarbon inhalational anesthetic commonly 
used for neurosurgical procedures.  A preliminary study evaluating the effects of 
isoflurane anesthesia on tonic glutamate levels in the rat hippocampus was 
conducted.  The subjects were animals already used for the experiments in 
Chapter Four upon completion of their use in that study.  Tonic glutamate levels 
were measured in each animal (unanesthetized), and then compared within 
animal to tonic glutamate levels obtained while under isoflurane anesthesia (2% 
in O2).  Animals represented all age groups and hippocampal subregions (n = 
15).  Isoflurane anesthesia did not significantly alter tonic glutamate levels 
(Paired t-test, p = 0.93, Figure A.1).  To confirm these results, glutamate was 
continuously measured as an animal awoke from isoflurane anesthesia.  No 
change in tonic glutamate was observed (Figure A.2). 
 An additional concern for future human glutamate recordings is MEA 
sterility.  We know that SG-2 MEAs are functionally robust following electron 
beam sterilization, but a sterile calibration protocol is needed to maintain MEA 
sterility during evaluation prior to in vivo use.  Pilot studies indicate that MEAs 
can be calibrated using sterile buffer and analyte (glutamate) (Table A.1), but 
additional studies are needed to determine if calibration parameters obtained 
with non-sterile and sterile buffer and analyte solutions are significantly different.  
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Figure A.1 Comparison of Tonic Glutamate Before and During        
Isoflurane Anesthesia 
 
Within animal comparison shows that measurements of tonic glutamate when 
animals were unanesthetized were not significantly different than when animals 
were anesthetized with isoflurane.  Mean unanesthetized basal glutamate = 16.5 
µM ± 4.0; Mean isoflurane basal glutamate = 16.3 µM ± 4.1.  Paired t-test, p > 
0.05. 
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Figure A.2 Tonic Glutamate Unchanged as Animal Recovers From 
Isoflurane Anesthesia  
 
Self-referenced recording of tonic glutamate showing no change after removal of 
isoflurane anesthesia (black arrow).  Some transient glutamate activity is seen, 
but overall basal glutamate remains stable until the animals is fully recovered and 
grooming (red arrow).    
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Table A.1 Comparisons of Non-sterile and Sterile MEA Calibrations 
 
Calibration Solution Slope (nA/µM) LOD (µM) 
Non-sterile PBS / Glutamate 2.1 0.3 
Non-sterile PBS/ Sterile Glutamate 2.3 0.2 
Sterile PBS/ Sterile Glutamate 1.6 0.2 
 
 
Copyright © Michelle Lee Stephens 2009
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